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Det finns inget sant som aldrig också är ljug 
Och ingen skillnad därmed, för den som är slug 
Det man bör betvivla är det huggna i sten 
För när sanningen är full står den på vingliga ben
  
 
  
 
ABSTRACT 
For women worldwide, the risk of developing breast cancer is second only to that of non-
melanoma skin cancer. Significant improvements have been made in survival over the past 
decades and today about 80 % of the patients survive 10 years or more after their breast 
cancer diagnosis. Still, far from all patients enjoy the relatively good survival indicated by 
statistics on breast cancer patients as one homogenous group. Improving prognostication of 
aggressive vs. less aggressive disease, and to separate tumors based on genetic differences for 
optimal treatment strategies, is therefore the focus of intensive research, including this thesis. 
 In paper I, we compared if tumor characteristics differ depending on what 
method of sampling the tumor that have been used for analysis. We compared routine 
immunohistochemistry on surgically resected breast specimens, including stains of the 
Estrogen receptor alpha (ER), the Progesterone receptor (PR), Human Epidermal growth 
factor receptor 2 (HER2) and the proliferation-associated protein Ki67, with analysis of the 
same stains done on material obtained from fine needle aspiration (immunocytochemistry). 
We found that there were substantial differences in the expression of these biomarkers 
between the two methods. Thus, the same rules for interpretation of biomarkers cannot be 
used for immunohistochemistry and immunocytochemistry, and consequently, validation of 
each method should be performed individually. 
 In paper II, we explored the scope of digital image analysis in biomarker 
evaluations. We scored ER, PR, HER2 and Ki67 status in several different regions of breast 
tumors by both manual methods and digital image analysis. The outcomes of the scoring of 
these biomarkers were then combined into IHC surrogate subtypes and compared to PAM50 
gene expression-based subtypes as well as patient survival. All tested methods of automated 
digital image analysis of Ki67 outperformed manual scores in terms of sensitivity and 
specificity for the Luminal B subtype. Comparing digital versus manual testing concordance 
to all breast cancer subtypes as determined by PAM50 assays, the digital approach was 
superior to the manual method. The manual and digital image analysis methods matched each 
other in hazard ratio for all-cause mortality of patients with tumors with a “high” vs “low” 
Ki67 index. Manual assessments of the biomarkers ER, PR, HER2 and Ki67 were in most 
aspects less precise than digital image analysis. 
 In paper III, we evolved the concept of paper I with an evaluation of the 
concordance of consecutive Ki67 assessments performed on fine needle aspiration cytology 
versus resected tumor specimens. We investigated how a status of Ki67 “low” and “high” as 
determined by immunohistochemistry and immunocytochemistry corresponded to overall 
survival, respectively. Again, Ki67-index varied when the two methods were used on the 
same tumors, and was prone to switch the classification between low and high proliferation. 
ER evaluations were discordant in 5.3 % of the tumors, which in the clinical setting would 
mean that 1 in 20 patients would risk being left out of beneficial endocrine treatment or being 
given it without benefit. Ki67 “high”, as determined by immunohistochemistry, defined as a 
proportion of Ki67-positive cells above the 67th percentile of the material, was significantly 
associated with poor overall survival and a significantly higher probability of axillary lymph 
node metastasis. This could not be reproduced for immunocytochemistry. In summary, this 
study adds to the results of paper I, in which we showed discordance between the methods. 
By including survival data, we now conclude that not merely are the methods discordant, but 
immunocytochemistry fails to provide prognostic information. Consequently, 
immunohistochemistry should be regarded as the superior method. 
 In paper IV, we focused on proliferation comparing the results in the tumors’ 
hot spot, in the tumor periphery, and as the average proportion of Ki67-positive cells across 
the whole tumor section. Both manual and digital scores of Ki67 and the recently described 
marker for mitotic activity, PHH3, were evaluated along with mitotic counts. Their sensitivity 
and specificity for the gene expression based Luminal B versus A breast cancer subtypes, for 
the high versus low transcriptomic grade, for axillary lymph node status as well as for their 
prognostic value for breast cancer specific and overall survival were analyzed. Digital image 
analysis of Ki67 in hot spots outperformed the other markers in sensitivity and specificity 
both for gene expression subtypes and transcriptomic grade. In contrast to mitotic counts, 
tumors with high expression of Ki67, as defined by digital image analysis and high numbers 
of PHH3-positive cells, had significantly increased HR for all-cause mortality at 10 years 
from diagnosis. When we replaced the manual mitotic counts with digital image analysis of 
Ki67 in hot spots as the marker for proliferation when determining histological grade, the 
differences in estimated mean overall survival between the highest and lowest grades 
increased. It also added significantly more prognostic information to the classic Nottingham 
combined histological grade. We conclude that digital image analysis of Ki67 in hot spots 
might be suggested as the marker of choice for proliferative activity in breast cancer. 
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1. INTRODUCTION 
1.1 THE MAMMARY GLAND 
1.1.1 DEVELOPMENT AND PHYSIOLOGY 
Along with distinct features such as the neocortex, viviparity and a skin at least partially 
covered by hair, the mammary gland is at the very core of mammalian life and evolution. 
This exocrine gland defines and enables the unique concept of offspring being nutritionally 
attached to the parent even after their mechanical separation, in turn a driver for advanced 
forms of social and communicative behavior. It gave early mammals the advantage of 
relatively fast juvenile growth rates and young fertility. As it reduces the dependence of 
different food supplies for young and old, it also facilitated adaptive behavior to the varying, 
and to the Dinosaurs overly challenging, ecological niches at the end of the Mesozoic (1,2) 
 On the individual level, the development and organization of epithelial-, 
mesenchymal-, immune- and endothelial cells that together form the mammary gland starts 
during embryogenesis and continues through adolescence and pregnancy until menopause, 
after which a degree of involution will occur (3). 
 Most stages of signaling pathways in embryogenesis overlap between different 
mammals, currently amounting to >5 000 species. Cells from the ectoderm layer, guided by 
the Wnt-signaling pathway, form the epithelial actively secreting component of the mammary 
gland. Cells from the mesoderm layer, guided by the fibroblast growth factor (FGF) pathway, 
form the stromal elements, which have a supporting role to the epithelium in both a 
mechanical, nutritional and functional sense (2,4). 
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Figure 1. Schematic representation of the mammary gland development in mouse. After 
embryonic day 10 (E10), the milk line (orange) breaks up into individual placodes (orange). 
Starting on embryonic day 15 (E15), the primary mammary epithelial sprout pushes through 
the mammary mesenchyme towards the fat pad (green). On E18, the duct has grown into the 
fat pad and has branched into a small ductal system. Modified from Robinson GW (5). 
Reprinted with permission from Nature Publishing Group. 
 
Ectodermal cells will form a milk line, and together with underlying mesenchymal cells a 
breast bud from which several primary sprouts project (Figure 1). These primary sprouts then 
elongate and branch, creating a ductal tree with thin end buds and open lumina. Paracrine 
communication between epithelial and mesenchymal cells via parathyroid hormone-related 
protein (PTHrP), and secreting factors such as insulin like growth factor 1 (IGF1) and the 
growth- and differentiation factor bone morphogenetic protein 4 (BMP4) plays crucial roles 
in this branching process in both mice and humans. Simultaneously, the epidermal layers of 
the skin form the nipple through thickening and suppression of the formation hair follicles. 
Before partus, a full mammary anlage is present for further development during childhood 
and puberty (2,5,6). 
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 In the childhood years, with an increased rate towards puberty, the hormonal 
changes in the female body lead to proliferational and functional stimulation of both stroma 
and epithelium of the mammary gland. In fact, the mammary gland is the only organ that 
undergoes most of its development postnatally (7). This leads to further elongation and 
branching of the end bud structures, thereby forming the functional unit of the mammary 
gland - the terminal ductal lobular units (TDLU) (3). 
 Apart from PTHrP and BMP4, growth hormone (GH), progesterone, prolactin 
and estrogen is increasingly important in this phase of mammary gland maturation (2,5,7). 
GH stimulates increased paracrine signaling of IGF1 from the local breast stroma as well as 
from its classic hepatic expression site (8,9). Estrogen is mainly produced in the ovaries and 
adipocytes while progesterone is produced in the corpus luteum and the adrenal glands. Both 
hormones are also produced in the placenta during pregnancy (7,9). Estrogen exerts its effect 
by binding to intracellular estrogen receptors (ER), of which two main subtypes exist: 
ERα and ERβ (10). During postnatal development, neither ER subtype is however 
significantly expressed in proliferating mammary epithelium, as the stimulatory effect of 
estrogen is rather produced through paracrine secretion, uptake and indirect ERα-activation. 
This has been illustrated in ER knockout mice, where only a few transplanted cells expressing 
ER is sufficient to rescue normal mammary growth (11). Members of the epidermal growth 
factor family (EGF) located in the stromal tissue, such as Amphiregulin (AREG), have been 
suggested as the active mediator in this paracrine secretion (2,12) Consequently, AREG is 
believed to promote much of the proliferation seen by estrogen stimulation (13,14). It is 
strongly induced in mammary tissue during puberty, and knocking out AREG or ERα in mice 
leads to similar phenotypes. Other candidates are the fibroblast growth factor (FGF) and one 
of its receptors (FGFR2) and the transforming growth factor β (TGFβ) with its receptor 
(TGFβR). Binding of the former induces the epithelium to elongate the glandular ducts, while 
binding of the latter inhibits the very same process and decreases duct density. Both are 
essential, as the ducts form the framework for alveolar outgrowth during pregnancy but an 
overly dense network of ducts would encroach on the inter-ductal space needed to form 
enough alveoli for milk production (Figure 2) (15-19). All of this perhaps serves as an 
illustration of the intimate relationship between the different cell types in the mammary gland 
and their molecular cross talk in the development and maturation of the organ during puberty. 
Estrogen signaling and ER, as well as progesterone receptors (PR) will be described in further 
detail in section 1.3, as they are two of the biomarkers of central interest in this thesis. 
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Figure 2. Overview of the events occurring during pubertal breast development. GH promotes 
cell proliferation by inducing the expression of IGF1 in both the liver and the mammary 
stroma. IGF1 acts, together with estrogen secreted from the ovary, to induce epithelial cell 
proliferation.  Estrogen signaling through its receptor (ER) acts via a paracrine signaling to 
stimulate the release AREG, which proceeds to bind its receptor on stromal cells and induce 
expression of FGFs, which in turn stimulate luminal cell proliferation. Other factors 
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contribute to mammary architecture by either positively or negatively regulating cell 
proliferation or maintaining cell-to-cell interactions. From Macias H et al 2012 (2). Reprinted 
with permission from Nature Publishing Group. 
 
During pregnancy, the mammary gland undergoes further changes to fully prepare for 
lactation. Stimulation from prolactin, human placental lactogen (HPL) and increased 
secretion of estrogen and progesterone, leads to budding of alveoli from the TDLUs in a 
process known as alveologenesis. While progesterone is not essential in pubertal or 
prepubertal mammary development, it is vital for alveologenesis (20-22). Absence of 
progesterone leads to hypoplasia of the TDLU while over expression of progesterone and PR, 
leads to abundant alveolar proliferation (24). The PR-positive cells lining the ducts do not 
proliferate at an increased rate during progesterone stimulation. Instead, the progesterone 
seems to promote proliferation in surrounding cells through paracrine signaling, similar to 
that of estrogen (21,23). 
 At partum, the delivery of the placenta results in a sudden drop in blood levels 
of progesterone, estrogen and HPL, which induces secretary activation and a sudden profuse 
milk production. Suckling by the offspring then triggers milk ejection through the nipple via 
release of oxytocin by the posterior pituitary, in turn leading to contraction of the 
myoepithelium -a smooth muscle layer of band-like cells surrounding the alveoli. The first 
milk released, the colostrum, is especially rich in white blood cells and IgA that helps protect 
an offspring with an immature immune system. Continued suckling over time, and thereby 
continuous prolactin secretion, maintain the production of milk in galactopoiesis. This also 
disrupts the pulsatile release of gonadotropin releasing hormone (GnRH) from the 
hypothalamus and hence luteinizing hormone (LH) from the pituitary, thereby preventing a 
new pregnancy (2, 21-26). 
 The involution of the mammary gland upon weaning of the offspring is a two-
step procedure. First, there is a vast apoptosis of the alveoli and TDLU. Second, the gland is 
remodeled into a structure very much resembling that of a nullipara, except the number of 
branches of ducts distal to the TDLU which remain close to that of the pregnancy (Figure 3) 
(2,3). 
 After menopause, further involution of the mammary gland takes place. 
Leading to epithelial structures and interlobular connective tissue being replaced by 
adipocytes and some degree of fibrotic connective tissue (1). 
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Figure 3. The mammary gland development from birth to involution. A: The mammary 
anlage is present at birth but remains inactive until puberty. B: During puberty, the epithelial 
ductal cells grow into the mammary fat pad, led by highly proliferative multilayered terminal 
end buds (inset 1). The multilayered epithelial body cells are surrounded by a single layer of 
epithelial cap cells. C: The mammary gland of a postpubertal nullipara is filled with mature 
epithelial branching structures. The ducts of this structure (inset 2) contain an outer layer of 
myoepithelial cells and an inner layer of luminal epithelial cells. D: Pregnancy induces 
hormonal changes that promote an expansion of alveolar cells, in turn evolving to milk-
secreting alveoli. The alveoli (inset 3) expand from the ducts now filling the major part of the 
fat pad. E: Upon weaning, involution proceeds through cell death and ECM remodeling, 
giving rise to a state that resembles the resting adult mammary gland. From Inman et al (27). 
Reproduced with permission from the Company of Biologists. 
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1.1.2 HISTOLOGY AND ANATOMY  
The human female breast consists of several types of tissue (Figure 4): Fat tissue, the pectoral 
muscles and the anterior chest wall will not be further elaborated on here as they are of 
relatively low interest in the perspectives of both physiological function and breast cancer.  
 The glandular tissue is organized into 15-20 lobes, arranged like petals in the 
frontal section. Each lobe consists of 20-40 lobules with 10-100 alveoli each, together known 
as the TDLU. Each alveolus is made up of epithelial cells, surrounded by myoepithelial cells 
and the basal membrane (3). The TDLUs drains into lactiferous ducts that gradually converge 
towards the nipple, where approximately 25 main ducts empty (3,26). 
 Both lobules and ducts are lined with a two-layered epithelium. The layer 
closest to the lumen of these structures consists of cuboidal milk producing cells, also known 
as luminal cells. The outer layer consists of contractile myoepithelial cells that helps push the 
milk produced in the TDLUs in the direction of the nipple. On the level of the myoepithelium 
are also mammary stem cells that can mature to either of the two epithelial cell types. These 
stem cells should not necessarily be confused with breast cancer stem cells, which will be 
discussed below. Myoepithelial cells and mammary stem cells rest on a basal membrane, in 
turn surrounded by stromal tissue (3,27) 
 The stromal tissue consists of extracellular matrix, peripheral nerves, blood- 
and lymphatic vessels. Among these are interspersed fibroblast, adipocytes, dendritic cells, 
macrophages and lymphocytes. At regular intervals, the stroma is organized into fibrous 
connective tissue septa, or suspensory ligaments, known as Cooper’s ligaments that help 
maintain structural integrity of the breast. Lymphatic vessels drain the mammary tissues to 
the axillary lymph nodes, in some individuals via intramammary lymph nodes (3). 
 Blood to the mammary gland is supplied through branches of the internal 
mammary- and the lateral thoracic artery. Starting during pregnancy and peaking during 
lactation, the blood flow increases to meet the demand of nutrients and oxygen of the 
mammary tissue. Naturally, this also increases the supply of immune cells and antibodies to 
the milk (3,26). 
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Figure 4. The different tissues of the human mammary gland. 1: Chest wall including ribs. 2: 
Pectoral muscles. 3. Breast lobes surrounded by stroma. 4: Nipple surface. 5: Areola. 6: 
Lactiferous ducts. 7: Adipose tissue. 8: Skin. Reproduced under a creative commons license. 
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1.2 BREAST CANCER, BACKGROUND 
1.2.1 EPIDEMIOLOGY 
Excluding non-melanoma skin cancer, breast cancer is by far the most common cancer and 
surpassed only by lung cancer as the most common cancer death in women worldwide (28). 
In 2012, there were an estimated 1.7 million new breast cancer patients and 0.5 million breast 
cancer specific deaths globally. The number of new cases per capita is still up to several times 
higher in developed countries, while mortality is higher in poorer countries (Figure 5) (29). 
The lower incidence in developing countries can chiefly be explain by a generally lower use 
of hormone replacement therapy, younger age at first child, higher number of children, older 
age at menarche, higher physical activity and less obesity. The relatively higher mortality on 
the other hand, is partially explained by lower access to screening programs and worse 
detection rates as well as less efficient healthcare for affected women, but genetically induced 
differences in risk cannot be ruled out (30-31). In concrete figures, 249 000 new invasive 
breast cancers (approx. 160 cases/100 000 women), 61 000 carcinomas in situ and 41 000 
breast cancer-related deaths (26 deaths/100 000 women), were expected in the U.S. in 2016 
(28). The figures in Western Europe including Sweden are similar on a per-capita basis, 
implying a female life time risk of obtaining the disease of 12.1 % (31). This can be 
compared to an incidence ranging from 11 to 45/100 000 women in Africa and mortality rates 
in the range of 10 to 35/100 000 women (33,34). In a historical perspective, survival has 
increased in both developing and developed countries. Since the 1970s, age-standardized 
mortality rates have been decreasing by roughly 1 % annually in the western world; ten-year 
relative survival has increased from around 40 % to at least 80 % today. Additionally, many 
western countries including Sweden have actually managed to decrease breast cancer 
incidence, or at least reduce it to a steady state, for women aged 50-64 years in the very last 
decade. This is attributed to reduced use of hormone replacement therapy for menopausal 
symtoms: current users of Oestrogen-progestagen combinations have a doubled relative risk 
for the disease (32), and perhaps increased awareness of liftestyle- and hereditary risks 
including susceptibility genes like BRCA1 and BRCA2 (28,29,31). 
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Figure 5. Estimated numbers (in thousands) of new cancer cases and mortality in women in 
more developed (left) and less developed (right) regions of the world in 2012. Modified from 
Ferlay et al (29). Reprinted with permission from John Wiley and Sons. 
 
1.2.2 THE HALLMARKS OF CANCER 
Cancer development is a complicated process, and even though remarkable progress toward 
understanding its mechanistic underpinnings has been made in the last decades, all details are 
yet to be understood. Cells acquire multiple changes on multiple levels from the DNA 
nucleotide sequence to the proteome, each driving them a step on their way towards 
malignancy. Naturally, the random and unspecific distribution of such changes implicate that 
most of them will lead to severe cell damage and apoptosis. Through natural selection, only 
the changes that happen to prolong cell survival, increase proliferation, induce invasiveness 
etc. will be accumulated throughout the tumorigenic process. 
 To enable comprehension of such a vital and faceted subject, systematization 
and some degree of simplification is warranted. The concept of “Hallmarks of cancer”, 
introduced by Hanahan and Weinberg in 2000 and updated in 2011, offers a simple and 
conceptual model of these changes, or capabilities, that a normal cell will have to acquire in 
the process of becoming malignant (Figure 6) (35,36). 
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Figure 6. The Hallmarks of cancer. As normal cells evolve progressively to a neoplastic state, 
they acquire a succession of these capabilities:  
1. Sustaining proliferative signaling 
2. Evading growth suppressors 
3. Activating invasion and metastasis 
4. Enabling replicative immortality 
5. Inducing angiogenesis 
6. Resisting cell death 
7. Genome instability and mutation (enabling characteristic) 
8. Tumor-promoting inflammation (enabling characteristic) 
9. Reprogramming energy metabolism 
10. Evading immune destruction 
Modified from Hanahan and Weinberg (36). Reprinted with permission from Elsevier. 
 
Evidently, these hallmarks are in no way mutually exclusive. Genomic instability for 
example, can be viewed as a prerequisite for generating enough genomic events to induce the 
other changes and is therefore identified as an enabling characteristic. Evading growth 
suppressors and resisting cell death are in some aspects overlapping entities, not least by the 
fact that many growth suppressors act to induce apoptosis.  
Point by point: 
1. Sustaining proliferative signaling 
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The ability to sustain chronic proliferation is very central to the research papers included in 
this dissertation, and presented by Hanahan and Weinberg as the most fundamental trait of 
cancer. In normal cells, the production and release of growth promoting signals is under 
careful control to maintain the tissue architecture. Cancer cells are however independent of 
this control, usually by activation of cell surface receptors containing intracellular tyrosine 
kinase domains. The activation can be triggered through autocrine secretion, an increased 
number of receptors or alterations in the receptor itself. Activation of the receptor in turn 
trigger branched intracellular signaling pathways that ultimately increase the cell’s 
progression through the cell cycle. Most of the proto-oncogenes, pathologically activated by 
point mutations, boosted promoter region activity, gene amplification, increased RNA or 
protein stability and/or a chromosomal translocation into oncogenes coding for oncoproteins, 
are involved in proliferative signaling by definition. In the context of breast cancer, 15-20 % 
of tumors profit from amplification of the ERBB2 gene, which leads to an increased 
expression of HER2 growth factor receptor and thereby increased proliferation (37). Further, 
the PIK3CA gene that transcribes the PI3K protein kinase is often constitutionally activated 
by mutations resulting in increased proliferation (38). The HER2 receptor will be elaborated 
on further below. 
2. Evading growth suppressors 
Cancer cells must circumvent extensive reactions to regulate growth. Tumor suppressor 
genes encode proteins that effectively block pathological proliferation, usually by activating 
programs for senescence or apoptosis. These operate as control nodes, in which metabolic 
stress, damage to the genome, suboptimal growth factor signaling etc. is discovered and acted 
upon. Many of these tumor suppressors function in larger networks leading to a degree of 
redundancy. The classic prototypes for these suppressors are the Tumor protein 53 (TP53) 
and retinoblastoma (RB1) genes. While the protein product of TP53 receives input from 
intracellular systems, the retinoblastoma protein integrates signals from diverse extracellular 
and intracellular sources. If abnormalities are discovered, both then work to inhibit the 
growth-and-division cycle. Evasion of these suppressors is thereby a prerequisite for the 
formation of many malignancies. This ability is normally acquired by loss-of-function 
mutations, deletions or downregulation of protein expression. In a two-hit model, loss of 
function of both alleles of RB1 is required for tumor formation. Indeed, children with a 
constitutional deactivating RB1 mutation need only a second somatic hit to develop 
retinoblastoma and other tumors, and have a relative risk of >40 000 of doing so (36,39). 
3. Activating invasion and metastasis 
Much like the overall concept of cancer hallmarks, tumor cells’ invasion and formation of 
metastases is not a single event but rather a multistep procedure. This encompasses a 
succession of cell changes, beginning with the capability to invade local tissues, then 
intravasation into nearby blood and lymphatic vessels and transit to distant sites, followed by 
extravasation, the formation of micro metastases and finally growth into macroscopic 
metastases. In the initial steps, many epithelial cancers have impaired cell-to-cell adhesion by 
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loss of the E-cadherin adhesion molecules. In the last decade, increased interest has been paid 
to this loss as a part of a larger cascade dubbed the epithelial-mesenchymal transition (EMT), 
in which a plethora of transcriptional factors including Snail, Slug, Twist, and Zeb1/2 have 
been identified. These drive the cells towards mimicking the machinery intended for wound 
healing and cell migration during embryogenesis. Further, crosstalk with stromal cells and 
macrophages surrounding the preinvasive epithelium has been found to prime these cell lines 
before invasion occur. The final step of adaption to a new environment and macroscopic 
detectable metastasis can take several years (36,40). 
4. Enabling replicative immortality 
With the exclusion of stem cells, normal cells can only perform a limited number of mitoses. 
Central to this limit are the telomeres that cap the ends of each chromosome. They consist of 
multiple hexanucleotide repeats and are successively shortened with each mitosis, ultimately 
leading to failure of protecting the chromosomal ends from end-to-end fusions, which usually 
triggers senescence or cell apoptosis. The length of these telomeres is thereby an indication of 
the number of divisions a cell can manage. Tumor cells obtain immortality by expression of 
the telomerase enzyme or by a closely related recombination mechanism, that both serves to 
maintain telomere length. In contrast to normal mature epithelium where no expression of the 
telomerase gene TERT is detectable, it is expressed in more than 90 % of invasive breast 
cancers (36,41). 
5. Inducing angiogenesis 
The increased proliferation, cell turnover and metabolic rate in solid tumors make for a high 
demand on nutrients and oxygen, as well as a mechanism for evacuation of accumulated 
waste and carbon dioxide. Naturally, recruitment of a rich vascular network is necessary 
before any tumor can grow into a macroscopically detectable lesion. Following an 
embryological model of angiogenesis otherwise only present in wound healing and the 
endometrial proliferative phase in the menstrual cycle, the tumor cells flip the balance of 
inducing and opposing factors to promote sprouting of new vessels. Factors secreted include 
the vascular endothelial growth factor (VEGF) and members of the fibroblast growth factor 
(FGF) family. Further, the presence of a premalignant lesion attracts macrophages, 
neutrophils, mast cells and myeloid progenitors that orchestrate an inflammatory reaction that 
contributes to the angiogenesis (35,36).  
6. Resisting cell death 
As mentioned previously, normal cells enjoy several parallel systems that inhibit excessive 
proliferation and accumulation of genetic damage. In addition to this, specific death-inducing 
signals can be administered through both extracellular and intracellular mechanisms in 
response to severe deviations from the normal state. The Fas ligand, belonging to the tumor 
necrosis factor (TNF) superfamily, is the archetype for extracellular death signals. In the 
intracellular domain, Bax and Bak dissolve the outer mitochondrial membrane and release 
cytochrome c into the cytoplasm. Both pathways culminate in a proteolytic cascade, triggered 
  14 
by the release of caspases and the start of the apoptotic program. Tumor cells, including 
breast cancer cells, can avoid these death signals by one or several processes: Increased 
expression of antiapoptotic BCL2 proteins, increased expression of survival signals like IGF1 
or by downregulation or deactivating mutation of apoptotic mediators including the Fas 
ligand receptor and TP53 (35,36,42). 
7. Genome instability and mutation (enabling characteristics) 
An unstable genome is the prerequisite for enough genomic events to make the other abilities 
possible. Tumor progression can be viewed as a succession of clonal expansions, of which 
each profit from chance acquisitions of enabling changes to the genotype. This is not the 
result of a will of the malignant or premalignant cells to become more aggressive, but rather a 
consequence of natural selection that eliminates all but the changes of the genome that 
increase survival and proliferation. Cancer cells eventually increase the rate of mutation by 
becoming more sensitive to mutagenic agents or by a breakdown in the genomic maintenance 
machinery like TP53 or DNA repair agents. BRCA1 and BRCA2 are DNA repair agents that 
protect the integrity of the genome. Having a germline mutation in either of these genes 
results in a greatly increased risk of developing breast cancer: 55 - 65 % of women who 
inherit a BRCA1 mutation and around 45 % who inherit a BRCA2 mutation will develop 
breast cancer by the age of 70 years (36,42,43). 
8. Tumor-promoting inflammation (enabling characteristics) 
The presence of an inflammatory response to virtually every neoplastic lesion is an 
established fact. Initially thought to represent an attempt to eradicate the tumor, these 
inflammatory responses are now seen as intimate partners and in more than a few instances 
promoters of the disease. Thus, the concept of tumor promoting inflammation has been 
coined. In this aspect, the inflammatory response mainly operates by supplying bioactive 
molecules to the tumor and its closest environment. This includes reactive oxygen species 
that break down cell membranes and are actively mutagenic, growth factors, proangiogenic 
factors, survival factors and enzymes that modify the extracellular matrix to aid invasion and 
metastasis (36). 
9. Reprogramming energy metabolism 
The increased rate of proliferation in cancer naturally requires an increased supply of energy. 
At first sight, it is therefore somewhat confusing that many cancers have a solid drive towards 
glycolysis even under aerobic conditions, with its 18-fold lower efficiency of ATP 
production. Glucose transporters like GLUT1 and the glycolysis promoting transcription 
factors HIF1α and HIF2α can be upregulated by both activated oncogenes like RAS and MYC 
and mutated tumor suppressors like TP53. The rationale from the cancer’s perspective is that 
it renders the tumor cells somewhat resistant to environmental conditions that would 
otherwise be very limiting to tumor growth. Hypoxia is common in the central regions of a 
rapidly expanding solid tumor. Further, glycolytic metabolites allow for synthesis of 
nucleosides, amino acids and the macromolecules and organelles required for the assembly of 
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new cells. In some tumors, a symbiosis has been found between glycolytic cells that secrete 
lactate and cells that import the lactate for use in the citric acid cycle, rendering the tumor 
somewhat self-sufficient in energy (36). 
10. Evading immune destruction 
Both the innate and adaptive arms of the immune system contribute to the defense against 
tumor formation, including tumors of non-viral etiology. Consequently, tumors will have to 
avoid or cooperate with the immune system to prosper. An example of this is that colon and 
ovarian tumors with dense infiltrations of cytotoxic T lymphocytes and natural killer cells 
have better prognosis than tumors that avoid such infiltrates (36). As mentioned in the 
“Resisting cell death” and “Tumor promoting inflammation” points above, other evidence 
suggests that tumors in other aspects can benefit from the interplay with the immune system. 
This serves as an illustration that compensatory mechanisms exist, that help cancer cells not 
only to avoid immune destruction but in some instances even prosper from the interaction. 
The molecular mechanisms behind this are not fully understood, but include recruitment of 
regulatory T cells and myeloid derives suppressor cells, secretion of immunosuppressive 
factors such as TGF-β and activation of the inhibitory CTLA-4 receptor on T-cells (36). 
 
1.2.3 BREAST CANCER GENESIS AND HETEROGENEITY  
The invasion of epithelial cells from the TDLUs through the myoepithelial layer and basal 
membrane into the surrounding stroma is the very definition of malignant breast cancer. The 
molecular steps behind this progression are not established in full detail. In many instances, 
the actual invasion is preceded by a morphological carcinoma in situ or hyperplastic stage 
where events that gradually change the genotype of both epithelial and myoepithelial cells are 
accumulated (44,45). 
 However, in contrast to a historic morphological theory of a linear progression 
through several increasingly severe premalignant stages before actual invasive disease, later 
evidence points to the fact that not all premalignant lesions lead to malignancy, and that not 
all malignancies are preceded by the premalignant morphological stages (40,44,45). 
Additionally, it is increasingly clear that breast cancer is not one single disease, but rather 
several different diseases originating from the same organ, with different prognosis and 
optimal treatments. These different diseases do not share all molecular characteristics, and 
thereby not necessarily the same molecular or morphological precursor states. 
 
The discovery of cancer stem cells has further challenged the idea of a successive progression 
of changes to mature epithelium. The cancer stem cell theory points out that cancer cannot be 
seen exclusively as a homogenous clonal expansion in which any cell has equal probability of 
driving further tumor development and proliferation. Indeed, the first potential candidate for 
breast cancer stem cells (BCSC) identified was over 50 times more tumorigenic than a 
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random population of its matured peers. This entails that a malignant or premalignant 
morphological state such as DCIS could be interpreted as the result of proliferation of a minor 
subpopulation of stem cells initiated by a founding stem-like cell, or at least a less 
differentiated cell, rather than the result of an initiating event to the entire region of the 
epithelium (46-49). 
 Note that BCSC should not necessarily be confused with the normal mammary 
stem cells that can be found in the deep layer of the epithelium. Their slow proliferation rate 
would make them quite unsusceptible to transcriptional errors and genomic instability. On the 
other hand, their potential for unlimited divisions and the lack of other candidates with stem 
cell-like properties still make the mammary stem cells worth mentioning in this context. 
 The stochastic plasticity model of the origin of breast cancer, interweaves with 
the concept of BCSC and theorizes that differentiated breast cancer epithelial cells have the 
potential to de-differentiate to a stem cell-like state, to form a clone that then drives further 
tumor growth and progression. This de-differentiation mechanism thereby signifies that the 
BCSC have acquired a stem cell-like phenotype, rather than being a clone with a stem cell-
like genotype. The de-differentiation is thought to occur very much like the epithelial-
mesenchymal transition previously described as one of the hallmarks of cancer (50-53). 
 Several immunohistochemical markers for the BCSC have been proposed, 
among which Cd44, Cd24, ALDH1, PKH26, DLL1 and DNER can be mentioned. Isolation 
of BCSC is further aided by their ability to form and proliferate in rounded clusters of cells 
called mammospheres without being inhibited or destined for apoptosis by loss of cell-to-cell 
contact. However, none of these techniques have complete sensitivity and specificity for all 
BCSC candidates, which still fuels some controversy over their existence (54-58).  
 Studies have shown that the concentration of BCSC is different in different 
breast cancer subtypes, and that they are less susceptible to conventional chemo- and 
radiotherapy. Several mechanisms have been proposed for the latter. For instance, the 
expression of detoxifying enzymes, efflux pumps and repair enzymes have been found to be 
upregulated, and the expression of death receptors to be downregulated in BCSC. The 
therapeutic targeting of these cells is thereby elusive. The DLL4 receptor, part of the Notch-
signaling pathway, has been proposed to be such a target. Others are the interleukin 8 
receptor and intracellular enzymes downstream in the JAK/STAT pathway. Considering the 
possibility of a switch between a differentiated and de-differentiated state however, specific 
targeting might only promote the state not targeted (59-69). Our own group have identified 
ERβ as a mediator of estrogen stimulation of BCSC but not differentiated breast cancer cell 
lines. Consequently, the ERβ-selective antagonist 4-[2-Phenyl-5,7bis (trifluoromethyl) 
pyrazolo[1,5-α]pyrimidin-3-yl]phenol (PHTPP) is a potent inhibitor of BCSC proliferation. 
Furthermore, inhibition of the mTOR pathway with agents such as rapamycin and everolimus 
significantly reduced mammospheres formation (70,71). 
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 At first sight, these findings are seemingly contradicted by the clonal evolution 
model, which offers a different perspective of cancer genesis and progression. In short, the 
model states that tumors progress by natural selection of the subpopulations of cells with the 
most advantageous characteristics at any given time. As such, this offers some explanation to 
the significant heterogeneity found within a tumor, which is a subject that defines a whole 
scientific field in itself. In fact, concept intratumor heterogeneity offers a way to reconcile the 
two seemingly contradictory concepts of cancer stem cells and clonal evolution. Given the 
increasing amount of research into tumor heterogeneity, both concepts can be valid. 
 Intratumor heterogeneity acknowledges the existence of different cell 
subpopulations within a tumor, or between a primary tumor and its metastasis, regardless if 
their differences are measured at the morphological, gene expression, protein expression or 
mutational load level. For instance, HER2 and Ki67-status may vary significantly between 
primary tumors and metastases, and both markers may also vary between different regions 
within the same tumor. Massively parallel sequencing has shown that both spatial 
heterogeneity, which signifies clonal differences across geographically separated regions of a 
tumor, and temporal heterogeneity, in which tumor tissue varies over time or with disease 
progression, are indeed common phenomena. Consequently, the differences within a tumor 
can be the result of both hierarchically arranged subpopulations founded by BCSC and clones 
that have evolved through natural selection (53, see also section 4.5) 
 
1.2.4 THE METASTATIC PROCESS 
Metastasis is a complex and only partially understood process. To be able to colonize a 
foreign anatomic site, the cancer cell must overcome a series of obstacles: these typically 
include separation from the original tumor and its surrounding tissue, invasion through 
barriers such as vessel walls, fasciae and basal membranes, intravasation and survival in 
blood- or lymphatic vessels, extravasation from these vessels, implantation and survival in a 
new microenvironment. Further, this needs to be followed by proliferation, angiogenesis, 
metabolic adaptation and avoidance of the immune system before these cells can generate a 
clinically detectable metastasis (35,36). 
 Nevertheless, metastasis is a common clinical issue, as breast cancer mortality 
is closely associated with disseminated disease but very rarely with the presence of a primary 
tumor only. In other words, patients with tumors restricted to the breast have a much better 
prognosis regardless of the other characteristics of that tumor. Recent investigations suggest 
that metastasis can be an early event, and that 60-70 % of patients have cancer cells that have 
undergone at least the early steps in metastasis at the time of discovery of the primary tumor. 
Further, up to one third of women without axillary lymph node metastases will still develop 
distant site metastases at a later point in time (72). Further insights into this process are 
therefore essential for improved diagnosis and treatment. 
Several models have been suggested for the metastatic process: 
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 The progression model is the classic theory that prevailed for decades, and is 
still regarded as valid in many aspects. It suggests that a metastasis is the result of a series of 
sequential mutational events to one or several clones of cells in the primary tumor, usually 
driving them towards a less differentiated state and eventually allowing for selection of a 
small fraction of cells with full metastatic potential. 
 The dynamic heterogeneity and the closely related extended transient metastatic 
compartment models were proposed as an explanation to the fact that disseminated cells in 
the circulation and metastases do not always have higher metastatic potential than their 
primary tumors. If dissemination and metastasis is always the result of a series of mutations 
that successively increase the metastatic potential, disseminated cells and metastasis would 
always be more inclined to generate further metastases than the primary tumor. However, this 
is not always the case. As a solution to this paradox, these models suggest that all cells in a 
primary tumor eventually acquire metastatic potential, but only a small fraction will be at the 
right location and in the right environment to be able to actually spread. Consequently, the 
cells that eventually form a distant metastasis might not be the clone with the very highest 
metastatic potential at a later point in time. 
 The horizontal gene transfer or genometastasis model suggests that metastatic 
growth can be induced not only by seeding of cells themselves from the primary to the distant 
site, but through uptake of circulating tumor DNA by cells with stem-cell like properties at 
the distant site. In this model, metastases could consequently be viewed as de novo tumors 
that have been induced by a form of genetic signaling from the primary tumor (72). 
 The early oncogenesis model applies findings of gene expression arrays 
pointing to the existence of several different gene signature profiles associated with risk for 
metastasis, both in the sense of intratumor heterogeneity within a bulk tumor and intertumor 
heterogeneity between different but in other aspects similar breast tumors. Consequently, this 
model gives some support to the original progression model, in that subsets of cells or tumors 
possess an inherent metastatic potential. This subset might however be so small in relation to 
the other populations of cells within a tumor that it might not always be possible to detect 
with tissue sampling (72). 
 As demonstrated by these brief accounts for several different models of the 
metastatic process, none gives a complete answer for all situations. Again, the different 
models are increasingly regarded as not mutually exclusive, but complementary and all 
needed for a thorough appreciation of the process. Quite possibly, all of them are correct at 
least in part, supporting the notion that there are several ways in which cancer cells can 
overcome the obstacles for metastasis presented here (see also subsection 1.2.2 on the 
hallmarks of cancer). 
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1.3 PREDICTIVE AND PROGNOSTIC FACTORS IN BREAST CANCER 
1.3.1 BACKGROUND -THE DIAGNOSTIC PROCEDURE 
After discovery of a suspicious breast lump through palpatory findings by the patient herself, 
by a doctor or through routine mammography, cells or tissue from that lump is usually 
sampled by a fine needle aspiration or core biopsy. Based on the pathologist’s findings in this 
cell or tissue analysis, and other relevant information from clinical and imaging 
examinations, the diagnosis of breast cancer and a plan for treatment is set. To an increasing 
extent, the diagnosis of breast cancer and the planning of treatment is the shared 
responsibility of a multidisciplinary team including pathologists, breast surgeons, oncologists 
and radiologists. 
 Several fundamentally distinct treatment modalities exist, including surgery, 
radiotherapy, cytotoxic chemotherapy, endocrine treatment and anti-HER2 therapy. 
 Neoadjuvant treatment, i.e. therapy given before surgical resection, can be 
considered in many clinical contexts: Generally, the aim is to reduce tumor size and axillary 
lymph node tumor burden and thereby downstage the disease. In some cases this allows for 
previously inoperable tumors to be radically resected. Cytotoxic chemotherapy is typically 
given for any high grade, large, axillary lymph node metastasized, ER negative, triple 
negative (ER, PR and HER2-negative), highly proliferative or HER2 overexpressing tumor. 
For HER2 overexpressing tumors, the clinical routine is to use dual blockade with HER2-
monoclonal antibodies trastuzumab and pertuzumab on a chemotherapy backbone, usually in 
the form of taxanes followed by anthracyclines. In the neoadjuvant and metastatic setting, 
lapatinib can be used instead of pertuzumab (in combination with chemotherapy and 
trastuzumab) with an increased ratio of pathological complete response. The side effects of 
lapatinib, mainly diarrhea and nausea, is however clearly higher with this regimen. For 
hormone receptor positive tumors, endocrine treatment is typically added (for further details, 
see section 1.5 on breast cancer treatment). 
 After surgical removal, the specimen is measured and weighed. Several gross 
samples from the tumor and surrounding tissue are then embedded in one block of paraffin 
each. These blocks are then sectioned, stained immunohistochemically as well as with 
haematoxylin and eosin and put on histopathological glass slides for examination under the 
microscope by the pathologist.  
 
Historically, breast cancer has been classified according to its histological appearance. Still, 
the World Health Organization (WHO) suggests a largely morphological classification of this 
heterogeneous disease, which remains a very important part in current clinicopathological 
routine. Here, carcinoma characterized as “no special type”, also known as ductal carcinoma 
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no special type or invasive ductal carcinoma, constitute the majority of invasive breast 
cancers (≈70 %). The designation comprises a heterogeneous group of tumors without the 
specific morphological characteristics that would classify them into one of the “special” 
subtypes. Hence, this is more or less a default diagnosis of invasive breast cancer. The most 
common of the special subtypes are lobular carcinoma, tubular carcinoma, mucinous 
carcinoma, carcinoma with medullary and apocrine features, micro papillary carcinomas, 
papillary carcinomas and metaplastic carcinomas (73).  
 A quite significant overlap in karyotype between these histological subtypes 
exists. Generally, a lower number of genetic aberrations have been found in lobular cancer 
compared to carcinoma no special type, which may reflect a generally lower histological 
grade of lobular cancer (further elaborated on in subsection 1.3.3). 
 Categorization according to the four gene expression-based ‘intrinsic’ subtypes 
“Luminal A”, “Luminal B”, “HER2-enriched” and “Basal-like” is a more novel and perhaps 
viable method of choice for prognostic and predictive value (subsection 1.3.4). A fifth 
frequently mentioned “Normal-like” subtype is excluded from many major documents, not 
least because it has been suggested to represent an artifact of contamination of tumor RNA 
with RNA from normal breast cells (Figure 7) (74-83). 
 
 
Figure 7. Relapse free survival for patients without adjuvant systemic therapy including 
HER2-targeted therapy across gene the expression based PAM50 intrinsic subtypes of breast 
cancer: Luminal A, Luminal B, HER2-enriched and Basal-like. Modified from Parker et al 
(78). Reprinted with permission from the American Society of Clinical Oncology. 
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However, gene expression tests are still expensive and time consuming, and expected to 
remain beyond the financial and practical boundaries of clinical practice for a few more 
years. This has created a demand for the cheaper and more readily accessible 
immunohistochemical (IHC) stains to act as surrogate biomarkers for the gene expression-
based subtypes. International expert consensus recommend primarily four such biomarkers to 
be evaluated during routine pathological work-up of resected or biopsied breast cancer tissues 
(74-76): the human epidermal growth factor receptor 2 (HER2), the estrogen receptor α (ER) 
and the progesterone receptor (PR) and the proliferation-associated nuclear protein Ki67. The 
latter has however not seen widespread use in the United States (these biomarkers are further 
described in subsections 1.3.5 to 1.3.8). Based on the status of the respective surrogate 
biomarker, conclusions can be drawn about the biological behavior, prognosis and surrogate 
subtype of the individual tumor, which in turn guide the treatment strategy (76,84-88) (Table 
1). 
 
 
Table 1. Gene expression based “intrinsic” subtypes of breast cancer and their surrogate 
classification based on immunohistochemical (IHC) stains of ER, PR, HER2 and Ki67. % = 
Proportion of tumor cells stained with the respective biomarker to the total number of tumor 
cells counted. ”Positive”, ”negative” = As defined by the American Society of Clinical 
Oncology and College of American Pathologists recommendations for human epidermal 
growth factor receptor 2-testing in breast cancer. “High”, “low” = Proportion of Ki67 above 
or below a threshold that should be predefined according to each laboratory’s own reference 
data. This threshold is generally in the range of 14-29 %. Adapted from international 
guidelines and other relevant publications (74-77, 85, 89-91). 
 
Consequently, it is very important that evaluations of biomarker status is sufficiently 
concordant with gene expression tests. Any dissimilarities in subtype classification between 
the two methods are associated with a risk of dissimilar conclusions of prognosis and 
divergent treatment decisions. If a specific therapy is indicated for patients with Luminal 
tumors as defined by gene expression tests, it might not be given to patients with tumors 
wrongly classified as non-luminal (Basal-like or HER2-enriched) with IHC. Conversely, 
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treatments with severe side effects such as cytotoxic chemotherapy might unnecessarily be 
given to patients if the IHC status suggests a more aggressive phenotype than gene expression 
tests. Unfortunately, evaluations of biomarker status do struggle with significant intra- and 
interobserver variability, as well as repeatedly shown dissimilarity with the gene expression 
tests (92). This is highlighted in the evaluation of Ki67, for which there is no general 
consensus on what number of cells to score in which tumor region, or even what threshold for 
the number of Ki67-positive cells (Ki67-index) that distinguish highly from lowly 
proliferative tumors (93-101). Although interobserver concordance have reached 99 % (κ 
0.95), 85 % (κ 0.85), 85 % (κ 0.70) and 85 % (κ 0.64) for ER, PR, Ki67 and HER2 IHC, 
respectively, with strict adherence to guidelines (95), thresholds and general definitions are 
considered unreliable outside individual laboratories’ own reference data (74,77,96). 
 A threshold proportion of Ki67-positive cells to the total number of assessed 
tumor cells in the range of 20 to 29 % have been suggested as one of the criteria to 
distinguish the more proliferative ‘Luminal B-like’ disease from the less proliferative 
‘Luminal A-like” disease. More specifically, a cutoff of ≥ 20 % for highly proliferative 
tumors is commonly used (75,76,97). The 2015 version of St. Gallen International Expert 
Consensus mention that the uncertainty and variability of IHC testing may be reduced by 
Image Analysis, but provide no concrete suggestions or details on how to apply this in 
practice (76). Improvements to the biomarkers’ prognostic value and congruence to gene 
expression tests are therefore a major aim of this thesis. 
 According to the National Institutes of Health biomarkers definitions working 
group, a biomarker, or biological marker, is defined as “a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic processes, 
or pharmacologic responses to a therapeutic intervention” (102). In other words, a biomarker 
is an objective sign of medical state that can be observed and measured from the outside of 
the patient. Examples of biomarkers include anything from blood pressure and visual acuity 
to laboratory tests on blood samples, immunohistochemistry and gene expression assays. 
Again, the immunohistochemical biomarkers ER, PR, HER2 and Ki67 provide surrogate 
value in both a therapy predictive and prognostic sense. ‘Therapy predictive’ denotes a factor 
that identifies an outcome of a specific therapeutic intervention. E.g. a hormone-receptor (ER 
and/or PR) positive breast cancer is expected to respond to treatment with an ER-antagonist 
like tamoxifen, cytotoxic chemotherapy is mainly effective on highly proliferative (high 
Ki67) and/or > stage I disease, and trastuzumab is expected to be effective for HER2 
overexpressing tumors. ’Prognostic’ denotes the biomarker’s ability to forecast the outcome 
for the patient, unrelated to given therapy. E.g. tumor size, histological grade and lymph node 
metastases. In this sense, HER2 and Ki67 are both therapy predictive and prognostic 
biomarkers since HER2 over expression and high concentrations of Ki67-positive cells in the 
tumor tissue implicate a poor prognosis (Table 2) (101,103-105). 
 Further details on Ki67, gene expression assays and other relevant biomarkers 
in breast cancer will be given along with the classic clinicopathological parameters below. 
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Therapy predictive biomarkers 
Correlate with outcome of a specific therapeutic intervention. 
Prognostic biomarkers 
Correlate with patient prognosis 
ER 
Ki67 
HER2 
Endocrine treatment (1.5.3) 
Cytotoxic chemotherapy (1.5.4) 
Anti-HER2 therapy (1.5.5) 
Tumor size (1.3.2) 
Lymph node metastases (1.3.2) 
Histological grade (1.3.3) 
PR (1.3.5) 
HER2 (1.3.6) 
Ki67 (1.3.7) 
Table 2. Examples of therapy predictive and prognostic biomarkers relevant to this thesis, as 
well as basic treatment regimens directly suggested by the former. Note that some biomarkers 
are both therapy predictive and prognostic. The correlation between biomarker and therapy 
response and prognosis is not necessarily positive. E.g. a higher proportion of Ki67-positive 
cells, but a lower proportion of PR-positive cells, indicate a worse prognosis. In several 
publications, PR has been regarded as a therapy predictive biomarker for intact signaling 
pathways of ER and thereby sensitivity to endocrine treatment, indicating that the distinction 
is not clear cut (24,136). Numbers in parentheses indicate subsections in which further details 
can be found. 
 
1.3.2 BREAST CANCER STAGE 
The 5-tiered stage of breast cancer (0 to IV) is determined by primary tumor size (T), 
presence of metastasis in loco-regional lymph nodes (N) or at distant sites (M), very much 
like most other solid tumors in the TNM classification system (103,104). 
 Stage 0 signifies that the tumor is non-invasive, i.e. a carcinoma in situ, 
commonly of the ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) type. 
These tumors have the very best prognosis. Stage I breast cancer signifies the earliest 
invasive stage with a 5-year overall survival (OS) well over 90 %. Stages II-III signify a 
gradually more fulminant disease for which therapy is generally intended to be curative. 
Stage IV indicates the presence of one or several distant metastases with a mean 5-year OS of 
only 12 % (103,104). Patients with stage IV disease can generally only be offered palliative 
treatment. 
 Disseminated cancer cells usually spread intravascularly in blood- or lymphatic 
vessels, and the presence of axillary lymph node metastases is indeed the very strongest 
prognostic factor in breast cancer. For the time being, any identified axillary lymph node 
metastasis suggest surgical removal of all detectable axillary lymph nodes with or without 
macroscopic metastases, which has been shown to reduce the risk of axillary recurrence. 
Whether it reduces the risk for distant metastases remains to be proven. The presence of one 
or several axillary lymph node metastases is a strong indication for systemic chemotherapy 
and extended radiotherapy. An extensive resection of 10-20 out of the total 30-40 lymph 
nodes in the axilla is however not done arbitrarily, as side effects in terms of lymphedema, 
pain and limited arch of movement can be quite substantial (106-116). 
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 To avoid unnecessary axillary dissections, the sentinel lymph node (SLN) 
technique with intraoperative lymphatic mapping in clinically node negative women has been 
generally accepted since the 1990s (106). A radiolabeled colloid is injected along with a dye 
in the peritumoral and periareolar area of the breast prior to surgery. The SLN is then 
detected using a gamma-ray detection probe in the axilla. At many institutions, the 
histopathological examination of the excised SLN is done intraoperatively with a frozen 
section evaluation for immediate feedback to the surgeon, who then can decide whether to 
proceed with a complete axillary dissection or not. If the SLN is free from metastasis, the risk 
for metastases in other locoregional nodes is very low. There is no evidence that axillary 
dissections increase survival in women without metastasis in the SLN (SLN-negative) upon 
histological examination (106-113). 
 In SLN-negative patients, the largest diameter of the primary tumor is the most 
important prognostic factor. The 5-year OS for primary tumors <10 mm is nearly 99 %, but 
only 86 % with a largest diameter of 30-50 mm (103-105). The introduction of 
mammography screening programs have decreased the average size of detected tumors to 
<20 mm in many western countries (105,108). 
 Naturally, both largest tumor diameter and presence of lymph node metastasis 
is included in the criteria for anatomic stage groups (Table 3a and 3b) (102,103). Newer 
versions of the AJCC Cancer Staging Manual also include extensive criteria for prognostic 
stage groups, where many of the prognostic and predictive biomarkers beyond TNM are 
included. The different factors described in this section should thereby not be seen as 
alternative (Table 4, at the end of this chapter) or interchangeable tests, but rather as parts of 
an extensive diagnostic work-up of breast cancer specimens that each contribute with parts to 
the full picture. 
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Table 3a. Definitions of pathological TNM categories for primary tumor (pT), regional lymph 
nodes (pN) and distant metastases (M). Measurements indicate greatest dimensions. ITC = 
isolated tumor cells. Numbers in criteria for pN indicate number of node metastases. 
Modified from AJCC Cancer staging manual 8th Edition 2017 (104). Reprinted with 
permission from Springer International Publishing. 
 
  26 
 
Table 3b. AJCC anatomic stage groups, combined from the TNM stages defined in Table 3a. 
From AJCC Cancer staging manual 7th Edition 2010 (103). Reprinted with permission from 
Springer International Publishing. 
 
1.3.3 HISTOLOGICAL GRADE 
A tumor’s grade is defined by how abnormal the cells and tissue look under a microscope. It 
is an indicator of how aggressive the tumor is, how quickly it grows and the risk for 
dissemination, whereas the tumor’s anatomic stage indicates how far this progress has gone 
without regard to the time frame or the way of doing so. The major method for defining a 
breast cancer’s grade is the Nottingham combined histological grading system, popularly also 
known as the Elston-Ellis grade (117,118). This dictates examination and quantification of 1) 
the remaining tendency for tubular formation, 2) the nuclear atypia and 3) the number of 
mitotic figures. Each parameter is given a score of 1 to 3, which is then combined into a total 
score of up to 9 points (117). All tumors can then be separated into one of three grades. Grade 
1 tumors have a total score of 3 to 5 points, grade 2 tumors a total score of 6 or 7 points and 
grade 3 tumors a total score of 8 or 9 points. Grade 1 tumors have the best prognosis and 
grade 3 tumors the worst (118,119). The intermediate histological grade, to which roughly 
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half of all invasive breast cancers are categorized, are associated with an intermediate risk of 
recurrence and limited value in clinical decision-making (120). In some reports, interobserver 
concordance in the grading of breast cancer have been disappointing: in a study where 93 
invasive breast cancers were evaluated at 7 different pathology departments, only 31 % of the 
tumors obtained the same histologic grade across all departments (overall mean kappa (κ) 
0.54) (121). Further, gene expression and transcriptome patterns of grade 2 tumors does seem 
to be a mix of either grade 1 or grade 3 tumors, rather than a distinct entity of its own 
(120,122). Analyses of chromosomal and genetic aberrations in different tumor grades have 
also shown that evolution from lower to a higher grade is quite rare, challenging the concept 
of a gradual progression from lowly to highly aggressive cancer in the fashion of tumor stage 
(52). An example of this is that loss of 16q and gain of 1q is common in grade 1 tumors but 
rare in grade 3 tumors, especially evident in luminal tumors (39,40,44). If a progression of an 
individual tumor from a lower to a higher grade was truly the case, these losses and gains 
would likely be retained, with additions of further changes from grade 1 to grade 2 and from 
grade 2 to grade 3. Conversely, grade 3 tumors commonly have aberrations of other 
chromosomes and relatively higher rates of HER2 amplification and lower rates of ERα and 
PR expression (45,52,65,120). 
 
1.3.4 INTRINSIC SUBTYPES 
For decades, classification of breast cancer was exclusively based on the histological 
appearance and clinical parameters described above. The diagnostic criteria for 
characterization and differentiation of each possible morphological appearance under the 
microscope (ductal carcinoma no special type, lobular carcinoma, tubular carcinoma, 
mucinous carcinoma, carcinoma with medullary and apocrine features, micro papillary 
carcinomas, papillary carcinomas and metaplastic carcinomas) are however far from clear-
cut, reducing its usefulness for clinical decision making (73). 
 Over the last two decades, gene expression studies have revealed that breast 
cancer is a heterogeneous group of diseases rather than one disease with several 
presentations. Perou et al. defined four different ‘intrinsic’ subtypes in 2000 (81): Luminal, 
Basal-like, HER2-enriched and Normal breast-like. Later studies have not established 
consensus that the Normal breast-like subtype is an actual form of breast cancer, as some 
propose it is rather a contamination of non-malignant cells to the breast cancer samples. 
Further, the Luminal group of cancers have been subdivided into a prognostically more 
favorable Luminal A subtype, and a less favorable Luminal B subtype. Other findings 
suggest additional but less often used intrinsic subtypes, such as interferon-rich, claudin-low 
and molecular apocrine (77,81). 
  The number of mutated genes have a positive correlation both 
with histological grade and intrinsic subtype, in the sense that the aggressive subtypes Basal-
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like and HER2- enriched have more mutations in TP53, NCOR1, NF1, PTPRD and RB1. As 
expected, this mutational burden is also associated with a worse prognosis (79). 
 Since individual tumors cannot be subtyped by hierarchical clustering, single 
sample predictors (SSP) have been developed. This allows for classification of individual 
samples based on their gene expression profiles. Later, the SSP has been developed further 
and the number of measured gene expression levels reduced to include panels of 7-70 genes 
(described below). 
 
Since the early 2000s, these gene expression-based arrays have seen increased clinical use. 
After analysis of the expression levels of thousands of genes, panels of 7 (Breast cancer 
index®) to 70 (Mammaprint®) genes that differentiate specific subclasses of breast cancer 
have been identified (77,78,80,81,84). The subclasses are in turn used for accurate 
prognostication in terms of the likelihood of relapse and distant metastasis (e.g. Breast cancer 
index®, OncotypeDx®, PAM50 and Mammaprint®), to identify a subset of hormone-
positive tumors with excellent prognosis with endocrine therapy only (e.g. Endopredict®) 
and to predict response to different therapies. By the PAM50 assay, in which the level of 
mRNA from 50 selected genes are measured, tumors can be assigned one of the “Luminal 
A”, “Luminal B”, “HER2-enriched” or “Basal-like” intrinsic subtypes, each with a different 
expected relapse free survival (Figure 7, Table 1) (74-77, 80-85). 
 The major watershed in the clustering of subtypes is the level of expression of 
hormonal receptors. Tumors with high expression of these, of which ERα and PR are the 
most important, are classified as luminal tumors. The name is derived from the gene signature 
of the ducts’ inner layer of luminal epithelial cells, which are the closest healthy relatives in 
the TDLU. Luminal A tumors have higher expression of cytokeratins 8 and 18 and hormone 
receptors, and lower expression of growth factor receptors and genes associated with 
proliferation, and thereby naturally a longer relapse free survival compared to Luminal B 
tumors (78). Among the hormone receptor-negative tumors, the Basal-like subtype express 
genes common in the outer lining of myoepithelial cells, like cytokeratins 5 and 14. HER2-
enriched tumors overexpress HER2 and genes associated to this receptor. Additionally, other 
classes such as the Claudin-low subtype with similar traits to mammary Cd44+/Cd24- stem 
cells and a Normal-like subtype with similar traits to normal mammary tissue have been 
proposed. As mentioned however, these are not included in major guideline documents and 
the latter has been suggested to represent an artifact of contamination of tumor RNA with 
RNA from normal breast cells (74-77, 80-85). 
 Even with the feasibility to run RT-PCR on a minor number of selected genes 
from FFPE, which has reduced cost and time consumption significantly, gene expression tests 
are still relatively expensive and time consuming compared to routine immunohistochemical 
stains. As the latter indicate the expression of certain genes on a protein level, which is not 
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necessarily an exact reflection of RNA levels and thereby not a measurement of the same 
parameter, they are referred to as surrogate markers for the intrinsic subtypes (76,77,102). 
 
1.3.5 HORMONE RECEPTORS 
Estrogen receptors belong to a nuclear receptor superfamily with nearly 50 members that 
show large structural similarities (123). This indicates that they stem from a common 
ancestor that later has developed minor variations inducing different physiological functions. 
Nuclear receptors are generally transcription factors that alter the transcription of select genes 
when activated (123-125). The first estrogen receptor (ERα) was discovered by Elwood V. 
Jensen in the 1950s while the second (ERβ) was discovered by Gustafsson and colleagues in 
the 1990s (126). Both are expressed in normal breast tissue and bind estrogen with equal 
affinity, which triggers proliferation of mammary epithelium. The gene for the 595 amino 
acids long ERα ESR1 is located on chromosome 6q while the gene for the 530 amino acids 
long ERβ ESR2 is located on chromosome 14q (127,128) 
 Approximately 70 % of all primary breast cancers are ER positive (129). 
Without regard to tumor stage, grade or intrinsic subtype in detail, hormone receptor positive 
tumors have a 5-year OS of 92 %, compared to 82 % for ER negative tumors (129). This 
difference in survival between luminal and non-luminal tumors tend to decrease slightly with 
longer follow up. Hence, it has been suggested that ER and PR expression should be used as 
a marker for a slower progression to metastasis and death, rather than a marker for the 
absence of it (105). 
 ER expression is also used as a predictive marker (129). Adjuvant endocrine 
therapy is the most important systemic treatment for hormone receptor positive tumors, and 
multiple endocrine therapies are currently available. The different classes include selective 
estrogen receptor modulators (SERMs) like tamoxifen, aromatase inhibitors (AIs) and the 
estrogen antagonist fulvestrant. In summary, these aim at estrogen deprivation, which has 
been shown to be anti-proliferative and improve prognosis even in tumors with miniscule 
proportions of cells immunohistochemically positive for ER (129-135). 
 ER and PR expression is strongly interlinked, where the latter is sometimes 
regarded as a marker of intact signaling pathways of the former. Conversely, the PR gene is a 
target of nuclear ERα activation by several upstream estrogen receptor-binding sites, or 
estrogen response elements (ERE). Therefore, it is believed that PR is a predictive indicator 
for endocrine treatment (24,136). However, there are currently no treatments specifically 
targeting PR. 
 A large retrospective study referred to by the 2015 version of St. Gallen 
International Expert Consensus found that tumors with a proportion of 1-9 % of cells 
immunohistochemically positive for ER and PR constitute a subgroup with recurrence free 
survival more closely tracking hormone negative tumors than tumors with higher ER and PR 
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positivity (76). Prat et al have pointed out a prognostic disadvantage of a PR positivity of < 
20 % within the Luminal spectrum of tumors (89). 
 Consequently, small differences in the results of ER and PR testing induces 
dissimilar conclusions about prognosis and predicted response to therapy. The most thorough 
guidelines for the IHC testing of ER and PR are provided by the American Society of Clinical 
Oncology and the College of American Pathologists. Among several important statements, 
these stress that up to 20 % of current IHC determinations of ER and PR testing worldwide 
may be inaccurate. Further, all tumor containing areas of a tissue section should be evaluated 
under the microscope, and at least 100 tumor cells counted for an average positivity across 
the tumor section. All tumors with ≥1 % of cell nuclei immunoreactive for ER or PR should 
be considered “positive” (133-138). 
 
1.3.6 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 
15-20 % of breast cancers have amplification of the ERBB2 gene on chromosome 17, from 
which the protein constituting the transmembrane human epidermal growth factor receptor 2 
(HER2) is transcribed (139). It is functionally and structurally a tyrosine kinase that drives 
proliferation (37). Thus, ERBB2 amplification and HER2 over expression is strongly 
associated with poor prognosis (105,140,141). Further, increased numbers of HER2 on the 
cell surface, with or without aberrations in the protein structure, can itself lead to ligand-
independent receptor activation (141-144). 
 With the advent of treatments targeting HER2, like the humanized monoclonal 
antibody trastuzumab in 1998, the relapse rate and overall prognosis for these patients have 
improved dramatically (see also subsection 1.5.5 on anti-HER2 therapy) (143). Thereby, 
testing of the expression of HER2 or ERBB2 amplification has become predictive for the 
response to this therapy. 
 Although a rather time consuming and complex procedure with an equivocal 
finding or positivity on HER2 IHC being followed by a mandatory determination of ERBB2 
amplification by HER2 Fluorescence in situ hybridization (FISH), the testing of HER2 status 
might be considered as one of the least controversial biomarker assessments in breast cancer. 
Again, the American Society of Clinical Oncology and the College of American Pathologists 
provides specific guidelines for the testing (91). Recently, a combined gene-amplification and 
protein over expression assay for assessment of HER2 status was made commercially 
available. This assay was also found to enable simplified and faster analysis without 
impairment of precision compared to separate IHC and FISH assays (145,146). 
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1.3.7 Ki67 
In addition to a count of mitoses when determining the histological grade, proliferative 
activity in breast cancer is commonly assessed by immunohistochemical staining of the 
nuclear Ki67 protein (74-76,147,148). Its name is derived from the city of Kiel, Germany, 
where the original clone was first discovered in position 67 of a 96-well plate. Just recently, it 
was discovered that Ki67 act as a biological surfactant that mediates the process in which 
chromosomes undergo reorganization into separate bodies to prepare for mitosis. Without this 
surfactant, they would simply collapse into a single cluster without potential for successful 
replication and division (149). Consequently, a large fraction of Ki67-positive cells indicates 
a large fraction of proliferating cells, or in other words: a fast growing tissue. It should 
however be noted that the MKI67 gene is actively transcribed in all phases of the cell cycle 
except G0 including in cells destined for apoptosis, possibly entailing high false positive rates 
(147). 
 Clinically, the proportion of Ki67-positive cells (usually expressed in percent) 
is important when deciding on which patients with hormone receptor positive tumors to give 
cytotoxic chemotherapy. High proportions of positive cells predict a good response to such 
treatment, while it also is an indication of a high risk for tumor relapse and distant metastasis. 
In terms of intrinsic subtypes, hormone receptor positive tumors with high proportions of 
Ki67-positive cells would classically imply a Luminal B designation and poor prognosis, 
while a low proportion would imply a Luminal A designation (74-76). 
 The value of Ki67 for determination of proliferative activity is supported by 
several studies, but so far, there is a lack of consensus on what tumor region and number of 
cells to score for a Ki67 index with highest clinical relevance. Further, while clearly high and 
clearly low values are reproducible, it has been very hard to establish a general threshold for 
dichotomization of these two (99,150,151). International collaborations and expert consensus 
have sought to define specific guidelines for the testing of Ki67. Currently, these describe 
three different approaches to what tumor region to assess under the microscope, depending on 
the distribution of proliferative activity across the tumor section: If the staining of Ki67 is 
homogenous without concentration of immunoreactive cells at the tumor periphery or in hot 
spots, ≥ 3 random high-power (×40 objective) fields should be assessed for a total of ≥ 1000 
cells (500 cells absolute minimum). If the staining of Ki67 is heterogeneous with increasing 
intensity towards tumor edge, ≥ 3 high-power fields at tumor periphery should be assessed for 
the same number of cells. If the staining of Ki67 is heterogeneous with increased intensity in 
hot spots, the whole tumor section should be assessed for an average Ki67 index. Local 
threshold values for distinction of Ki67 “high” and “low” should be defined using each 
laboratory’s own reference data (74,77,97). Currently, this threshold is commonly in the 
range of ≥ 14-29 % for Ki67 “high”, derived from the number of Ki67-positive tumor cells 
divided by total number of counted tumor cells (Figure 8) (74-77,97,100,101). 
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1.3.8 PHOSPHO-HISTONE H3 
Histone H3 is one of the five main highly alkaline histone proteins involved in the structure 
of the chromatin in eukaryotic cells. Together with the DNA strand and eight units of such 
histone proteins they form the nucleosome, the basic unit of DNA packaging (152). Recent 
studies with an antibody against Ser-10 phosphorylated H3 (PHH3) demonstrate a tight 
correlation between PHH3 and mitotic chromatin condensation (153). 
 In contrast to Ki67 that is expressed in all phases of the cell cycle except for G0 
(154), phosphorylation of histone H3 occurs exclusively in late G2 and M-phase and does not 
occur in cells undergoing apoptosis. Thus, it is both in theory and practice a very specific 
marker for mitotic activity. Studies on immunohistochemical staining of the histones have 
been showing promising results throughout almost a decade, but this approach has so far not 
been introduced in clinical practice nor included in guideline documents (Figure 8) 
(76,152,153,155). 
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Figure 8. Comparison of immunohistochemical stains of the pancytokeratin marker 
CkMNF116 (top) that is positive in all epithelial (tumor) cells but negative in the surrounding 
stroma, Ki67 (middle) and PHH3 (bottom) in the same region of a breast cancer. Note the 
relatively small fraction of tumor cells being stained by PHH3 (2 out of 259 tumor cells = 0.8 
%) compared to Ki67 (55 out of 259 tumor cells = 21 %), which exemplifies their different 
presence during the cell cycle. In contrast to Ki67 that is expressed in all phases of the cell 
cycle except for G0 including cells underway to apoptosis, phosphorylation of histone H3 
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occurs exclusively in late G2 and M-phase and does not occur in cells undergoing apoptosis. 
Modified from the author’s own material. 
 
1.3.9 NATIONAL VS. INTERNATIONAL GUIDELINES FOR BIOMARKER 
TESTING 
The Swedish Quality- and Standardization Committee (KVAST) propose regularly updated 
national guidelines for biomarker testing in breast cancer (98). Generally, these closely track 
international guidelines on biomarker testing that have been mentioned for each factor in 
subsection 1.3.5 through 1.3.8 (Figure 9). All analyzes are to be validated by both test- and 
population level quality controls such as NordiQC (nordiqc.org)/UK Neqas (ukneqas.org.uk) 
and SweQA/Equalis, respectively. External controls from endometrium, cervix or cell lines 
are to be included on each tumor slide. Positive staining is defined as any brown stain in the 
nucleus above background. As PHH3 is not used in clinical breast cancer diagnostics, no 
guidelines have been developed. In paper IV of this thesis, PHH3 was scored according to the 
recommendations for mitotic counts. 
 In some details however, the national guidelines differ from the international 
guidelines on biomarker testing, in that they: 
1. Exclusively focus on tumor regions with the highest proliferative activity (hot 
spots) for Ki67 assessment (97,98). 
2. Recommend a different number of cells to be counted in assessment of Ki67 index 
(Swedish guidelines: ≥ 200 cells. International: ≥ 1000 cells with 500 cells as an 
absolute minimum) (97,98). 
3. Have a higher threshold for classification of a tumor as ER and PR positive. In the 
Swedish guidelines, this cutoff is actually not spelled out, but a proportion of 10 % 
stained cells is generally used, although endocrine treatment can be considered for 
patients with lower positivity. This is also the parameter (proportion of cases with 
ER >10 %) recommended to be reported to the Swedish National quality register. 
The 2015 version of St. Gallen International Expert Consensus (76) define this 
threshold as 1 %, but add that ER values between 1% and 9% are equivocal and 
that patients with these values cannot rely on endocrine therapy alone. In clinical 
practice, the outcome of the Swedish vs. international guidelines on ER should be 
very similar. 
4. Have a lower threshold for amplification of the HER2-gene. According to the 
Swedish guidelines, a single-probe average HER2 copy number of ≥ 4/cell defines 
gene amplification and an indication for trastuzumab. The U.S. guidelines define an 
average copy number of 4 to 6/cell as “equivocal” with a recommendation of reflex 
testing, and ≥ 6 as the threshold for amplification (91,98). 
5. Emphasize that the pathologist informs the referring clinician on what clones of 
antibodies and ISH probes, what lab equipment and makes of machinery including 
names of its suppliers have been used in each assessment of a biomarker. Neither 
the necessity for this nor the clinical demand for it is underlined in international 
guidelines (98,75-77). 
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Figure 9. Flow chart for the classification of surrogate subtypes of breast cancer based on 
protein expression assessed by immunohistochemistry. Modified from the Swedish Quality- 
and standardization document for breast tumors, Ekholm et al (98) with permission from the 
author. “pos” and “neg” = immunohistochemically positive and negative, respectively. 
Threshold for ER not specified, generally 10 %. HER2 positive if IHC 3+, IHC 2+ and ISH 
HER2 copy to C17 ratio ≥ 2 or IHC 2+ and HER2 copy number >4. Ki67 is divided into 
three groups, where all cases below the 34th percentile in each laboratory’s own reference 
data are classified as low, all cases between the 34th and the 58th percentile as equivocal, and 
all cases above the 58th percentile as high. NHG1 and NHG3: If ER, PR, Ki67 and HER2-
status indicate a Luminal A-like subtype but the Nottingham combined histologic grade is 3, 
a new assessment of both the biomarkers and grading is indicated. If the NHG is still 3, the 
tumor should be classified as Luminal B-like. Vice versa: If the biomarkers indicate a 
Luminal B-like tumor but the NHG is 1, and this is confirmed in a new assessment, the tumor 
should be classified as Luminal A-like. These guidelines differ in some details, but not in 
general from the definitions for surrogate subclassification used in the papers presented in 
this thesis (Table 1). 
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1.4 DIGITAL IMAGE ANALYSIS 
1.4.1 SOFTWARE 
In its most basic definition, image analysis is the extraction of information from images 
(156). In this sense, all examinations of tissue since the dawn of the light microscope in the 
17th century, and all conclusions drawn from the visual appearance of these tissues, would 
classify as image analysis. Where the analysis previously has been the exclusive task for a 
human observer however, it can now to an increasing extent be assigned to digital image 
processing techniques. Hence the term computer image analysis or digital image analysis 
(DIA). The latter will be used in this thesis and the included scientific papers. 
 Originally developed in the fields of artificial intelligence and robotics, the first 
versions of software capable of pattern and geometry recognition and processing were 
presented in the 1970s. It is now a scientific field of its own with a plethora of private sector 
spin-offs and both free-to-use and commercially available software available (156-159). In 
medicine, these can be applied to anything from the estimation of tumor volumes in 
mammography and differential leukocyte counts to the assessment of 
immunohistochemically stained cells in tumor sections. The evolution of this wide variety of 
software has been compared to a natural selection, where only a portion of gradual changes 
over the last 40 years have been retained based on unsentimental evaluations of what’s being 
used and functional, and what’s not (157). Currently, most algorithms incorporate all of 
pattern recognition, texture analysis, densitometry and digital signal processing that basically 
compare and analyze patterns, contrast and colors of the pixels making up the image. Having 
previously only been feasible to run on super computers or clusters of several smaller 
computers, these algorithms are now simple enough to run on off-the shelf laptop or desktop 
computers. In addition to the challenge of image size and efficient logistics mentioned below, 
they still have to overcome the challenge of varying file formats as each scanner 
manufacturer tend to use its own proprietary image compression. For example, Aperio 
scanners, sold by Leica Biosystems, Wetzlar, Germany, store their images as .SVS-files, 
based on a standard pyramid tagged image file format (TIFF) and use a red, green, blue, alpha 
color model, while NanoZoomer scanners, sold by Hamamatsu Photonics, Hamamatsu, 
Japan, store their images as .NDPI-files, based on a stripped TIFF format that save colors in a 
different order: Blue, green and red. This serves to exemplify that thresholding, i.e. 
determining whether a group of pixels with a relatively intense color signal constitutes a 
positively stained cell nucleus or not, is merely one of several end-games of DIA. Between 
slide scanning and actual analysis, several preparatory steps will have to be successfully 
completed (156). 
 The validation of DIA will henceforth be limited to its application for 
immunohistochemical stains of ER, PR, HER2, Ki67 and PHH3 in their predictive and 
prognostic functions and as surrogates for gene expression profiles. 
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 As mentioned in subsection 1.3.1, recent international guidelines state that the 
uncertainty and variability in the testing of these biomarkers in breast cancer may be reduced 
by Image Analysis (76). The emerging plethora of DIA-systems have shown excellent 
reproducibility and accuracy, though so far in subsets with individual biomarkers or smaller 
populations (160-164). 
 Modern software for DIA in pathology distinguish between tumor and non-
tumor tissue, requires relatively few manual commands before analysis and present the data, 
i.e. the fraction of Ki67-positive tumor cells, in a quick, systematic and comprehensible way. 
Costs ranges from free open source-solutions where users can add, change and develop new 
applications, like the public domain, Java-based software ImageJ, originally developed at the 
National Institutes of Health, to advanced licensed software for which the user pay in excess 
of 20 $ per tumor slide (Figure 10) (165,166). 
 Note that software for DIA should not be confused with picture archiving and 
communication systems (PACS), that are aimed at providing storage, convenient access and 
facilitating workflow in radiology and digital pathology. These are generally not involved in 
actual analysis of images, but are often offered as parallel systems to systematically handle 
the large volumes of images and data generated when DIA is used in clinical routine. In many 
cases, DIA applications and functions can be incorporated into PACS (167). 
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Figure 10. Example of a result image from a free web application for automated image 
analysis of ER, PR and Ki67 immunohistochemically stained and digitally scanned tissue 
sections. The result image includes a sample identifier, the analysis date, the labeling index 
(percentage of Ki67-stained tumor nuclei to total number of tumor nuclei), the original image 
(top), and a pseudo-colored image showing the segmented staining components (bottom). 
Positive cells = orange. Negative cells = blue. Reprinted from Tuominen et al (165) under a 
creative commons license. 
 
1.4.2 SLIDE SCANNING 
Any image analysis, manual or digital, requires a properly lighted, focused, sized, projected 
and formatted image. In addition to the nearly 200 years old prerequisites of proper fixation, 
dehydration, embedding, sectioning and staining of tumor tissue for the production of 
histopathological glass slides, DIA requires that a high quality image be generated through 
digital scanning (156,166-169). 
 The first step in this process is to insert the glass slide in a digital scanner, either 
in single units or multiple on a tray. Currently most scanners are adopted for the standard 75 
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× 25 mm (3′′×1′′) size glass slides. Approx. 300 of these slides can be loaded into high 
throughput scanners (Figure 11). 
 
Figure 11. Left: Example of a whole slide imaging scanner (top) and PACS from the same 
manufacturer (Omnyx®, bottom). Virtual slide composed of multiple image aqcuisitions 
from a physical glass slide. Right: List of currently available commercial whole slide 
scanners. Modified from Farahani et al (170), reprinted under a creative commons license. 
 
The second step of the digitization process is then to decide on what area or region of the 
slide to scan. Virtually all scanners offer a pre-visualization tool, which projects overview 
images. From these, the tumor or region of interest can be outlined to avoid unnecessary data 
generation or disturbing artifacts (169). 
 The third step is to adjust the focus point and focus depth for the selected region 
and adjust image settings, such as white balance, contrast, scanning magnification etc. 
Naturally, most manufacturers offer the possibility to have the scanner automatically identify 
regions of interest, multiple point focus depths and image settings. Further, there is usually an 
option to scan the entire glass slide or a predefined subset of it without regard to the location 
and orientation of the tissue on an individual slide. 
  40 
 The fourth step is the actual scan. Several objectives, each focused on a 
different field, or one moving objective delivers images to a digital camera. The most 
common solution is acquisition of the microscopic fields square-by-square, from the slide’s 
upper left corner to the lower right (tile-based method). Alternatively, the moving objective 
travels over the slide in a straight line, moving in the Y-axis only after reaching the edges of 
the scan area (line-based method, Figure 12) (169,170). The small individual images are then 
adjoined to create a seamless virtual slide. As the objectives are generally scanning at 20 – 
60x, each generating an acquisition with a field diameter of approx. 0.9 to 0.3 mm, the virtual 
slide is a mosaic that can consist of several hundred individual images, allowing for free 
movement from an overview magnification of the whole slide down to individual cells (156). 
 If a monochromatic camera is used, three sequential scanning rounds are 
required (for red, green and blue), thereby tripling the amount of data per acquisition. The 
total size of a whole slide scanned on a modern scanner is generally in the range of 100 
megabytes to several gigabytes, and can contain more than a billion pixels (156,169). 
 After the scan process is finished, the images are imported as individual files to 
folders on a receiving computer, to a PACS for archiving or to the DIA software for analysis. 
 
 
Figure 12. Illustration of (left) a tile-based and (middle) line-based scanning method. (Right) 
Line-based scanning of an actual glass slide in progress. Modified from Farahani et al (170), 
reprinted under a creative commons license. 
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1.5 BREAST CANCER TREATMENT 
1.5.1 SURGERY 
Surgical removal of tumorous tissue is the main pillar of breast cancer treatment. For a 
majority of patients, the procedure is curative. For small primary tumors (<5 cm, anatomic 
stage I or II, Table 3a and 3b), the removal of the tumor along with all mammary tissue 
(mastectomy), and breast conserving surgery (BCS) where the cancerous lump is removed 
with an attempted surgical margin of 1 cm are equally safe in terms of prevention of 
recurrence and metastasis (130,171,172). In other words: extensive removal of tissue does not 
prolong survival in these patients. All patients, except lymph node negative T1-T2 tumors 
treated with mastectomy, benefit from postoperative radiotherapy (130). For women without 
clinically detectable axillary lymph node metastases, the sentinel lymph node technique with 
intraoperative lymphatic mapping has earlier been considered gold standard, but is now 
seeing decreased use in many institutions in favor of FFPE tissue (105) (see also subsection 
1.3.2 on breast cancer stage). If the SLN is free from metastasis, the risk for metastases in 
other locoregional nodes is < 7.5 % (106). There is no evidence that axillary dissections 
increase survival in women without metastasis in the SLN (SLN-negative) upon histological 
examination (106). The 5-year OS for patients with SLN-negative disease is 83 %. If 1-3, 4-
12 and ≥13 axillary lymph nodes are positive for metastatic growth, the 5-year OS is 73, 46 
and 29 %, respectively (106-113). If distant metastases are present (stage IV), surgery is less 
favorable and generally aimed at reducing tumor mass and symptoms.  
 
1.5.2 RADIOTHERAPY 
Radiotherapy is commonly directed at the surgical bed to reduce the risk of recurrence and 
distant metastasis. In this setting, repeated fractions of small doses, e.g. 2 Gy/day for 25 days, 
or more recently in more intense “hypo fractions” of >2 Gy/day for a fewer number of days, 
are given to reduce side effects (172,173). After BCS, radiotherapy to the conserved breast 
halves recurrence rates and reduces the breast cancer death rate by a sixth (172). Further, 
meta-analyses have shown that postoperative radiotherapy improves survival not only after 
BCS, but also after mastectomies (174,175). Expert consensus recommend post-mastectomy 
radiotherapy for patients with axillary lymph node metastasis, for tumors >5 cm regardless of 
nodal status and after resections with positive deep margins (76). Swedish guidelines 
recommend postoperative radiotherapy to all patients except lymph node negative T1-T2 
tumors treated with mastectomy, and patients with T1-T2 tumors and micro metastasis (0.2-
2.0 mm) in 1 lymph node only that have undergone mastectomy and adequate axillary 
dissection of ≥ 10 lymph nodes (130). 
 The benefit of radiotherapy increases with markers for aggressive disease, like 
histological grade and proliferational rate. This is an indication of its mechanism of action: 
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Photons or charged particles causes direct or indirect ionization of the atoms that make up the 
DNA chain, causing double-stranded breaks which in turn causes relatively more harm to 
tissues consisting of highly proliferational cells with malfunctioning DNA repair mechanisms 
(176,177). A degree of damage to surrounding healthy tissues is however unavoidable, and 
radiotherapy is consequentially associated with significant morbidity, such as pleuritis, lymph 
edema, neural damage and skin rashes (178,179).  
 
1.5.3 ENDOCRINE TREATMENT 
Antagonists to ERα, or inhibition of estrogen production, is beneficial for both pre- and 
postmenopausal patients with hormone receptor positive tumors (180,181). The metabolites 
of tamoxifen - the most widely used and tested drug in breast cancer, compete with estrogen 
for the binding of ER. Thereby, the transcription of estrogen-responsive genes is reduced 
(180). Treatment for 5 or 10 years after surgery reduces the risk of recurrence by nearly 50 % 
and significantly improves overall survival (181). 
 Aromatase enzymes convert androgens into estrogens. Blockage of this 
conversion with AIs leads to lower levels of estrogens available for hormone receptor 
positive tumors (182,183). Like the regulation of most endogenous hormones however, 
reduction of the downstream effector is compensated for by increased production of the 
substrates. Decreased concentrations of estrogen will activate the hypothalamus and pituitary 
to secrete gonadotropin, which in turn will stimulate aromatase promoters and competent 
ovaries to increase androgen production. The effect of AIs is thereby counteracted. 
Consequently, AIs like anastrozole and exemestane is only used in postmenopausal women, 
where estrogen is mainly produced in peripheral adipose tissue (183,184). AIs are slightly 
more effective in preventing recurrence than tamoxifen, and comes with a lower risk of 
thromboembolic events and endometrial cancer. Osteoporosis and muscular pain is however 
more common in patients treated with AIs (185-187). 
 Despite both tamoxifen and AIs being effective treatments for hormone 
receptor positive tumors, hormone receptor positive relapses do occur. Significant efforts 
have been made to understand the mechanisms behind this. Among many discoveries, it has 
been shown that a shift from estrogen dependent- to estrogen independent growth has 
occurred in as many as 20 % of tumor relapses (188,189). Other mechanisms behind relapses 
are constitutional phosphorylation of both nuclear and membrane-bound ERα, leading to 
ligand independent activation, truncated variants that activate transcription even in the 
absence of hormone and a switch in the ratio of coactivators versus corepressors (189-192). 
Another obstacle to fully successful endocrine treatment is compliance. Taking one pill a day 
for 5 or even 10 years with adverse side effects and no instant benefit means that as many as 
31 % of patients do not adhere to treatment recommendations (193,194). 
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1.5.4 CYTOTOXIC CHEMOTHERAPY 
Cytotoxic treatment regimens are indicated for a broad group of both pre and postmenopausal 
breast cancer patients. A combination of drugs such as fluorouracil, epirubicin, 
cyclophosphamide (FEC) followed by a taxane such as docetaxel or paclitaxel is beneficial 
even for early stage ER-positive disease without axillary lymph node metastases but with at 
least one high risk feature such as a high histological grade 3, high Ki67 expression, or other-
than-Luminal A subtype (130). For stage III and IV disease, chemotherapy is nearly always 
recommended (75,76). In stage I-III patients, chemotherapy reduces mortality and risk of 
relapse significantly. Relative risk reductions of 22 to 36 % have been reported (195,196). 
 The most common combinations of drugs are fluorouracil, epirubicin, 
cyclophosphamide (FEC), cyclophosphamide, methotrexate and fluorouracil (CMF), 
fluorouracil, doxorubicin (formerly Adriamycin) and cyclophosphamide (FAC), epirubicin 
and cyclophosphamide only (EC) and doxorubicin and cyclophosphamide only (AC) 
sometimes followed by paclitaxel (76,195-197). All of these target vital elements in cellular 
division, often inducing severe genetic damage that targets the cell for apoptosis. This 
illustrates the relatively higher static and toxic effect in highly proliferative tumors. 
Consequently, side effects to normal highly proliferative tissues like the gastrointestinal tract, 
hair follicles, skin and immune system is quite severe. Other side effects of cytotoxic 
chemotherapy include nausea, infection, phlebitis, thromboembolism and a risk for secondary 
malignancies (196,197). 
 The rising concept of neoadjuvant treatment, often with combinations of AC or 
FEC that can be followed by docetaxel, paclitaxel or carboplatin, to reduce tumor size before 
surgical resection, is recommended for patients with locally advanced or inoperable tumors 
(130). This includes stage III and IV disease, axillary node fixation and supraclavicular or 
parasternal metastases. This aims to reduce tumor size and axillary lymph node tumor burden 
and thereby downstage the disease. In some cases this allows for previously inoperable 
tumors to be radically resected. In a large Cochrane review, even primarily operable patients 
could be offered neoadjuvant treatment without decreased survival versus adjuvant regimens, 
but with the benefit of reducing the frequency of mastectomies in favor of BCS (196). For 
HER2 overexpressing tumors, chemotherapy can be combined with dual HER2 blockade in 
the form of trastuzumab plus pertuzumab in both the neoadjuvant and metastatic setting 
(further details in subsection 1.5.5. on anti-HER2 therapy) (76,130,198-200). 
 
1.5.5 ANTI-HER2 THERAPY 
ERBB or Human epidermal growth factor receptor (HER) -signaling is a receptor-ligand 
system of four receptors and more than eleven ligands. Receptor expression generally occurs 
in epithelial tissue, whereas the ligands are synthesized in the stroma. The four different types 
of HER are rarely expressed alone or without their co-receptor ERBB2. The system as a 
whole is frequently over-activated in proliferative diseases, including breast cancer, psoriasis 
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and arteriosclerotic plaques. It is functionally and structurally a tyrosine kinase, and functions 
as an oncogene. Consequently, it has gained much interest as a therapeutic target (201-203). 
 As described in subsection 1.3.6, 15-20 % of breast cancers have amplification 
of the ERBB2 gene on chromosome 17, from which the protein constituting HER2 is 
transcribed (139). ERBB2 amplification and/or HER2 over expression is associated with poor 
prognosis (105,139). Further, increased numbers of HER2 on the cell surface, with or without 
aberrations in the protein structure, can itself lead dimerization and ligand-independent 
activation of the receptor (139-142). 
 The humanized monoclonal IgG1-antibody trastuzumab was developed in the 
1990s. It has high affinity for the juxtamembranous domain IV of the extracellular receptor 2 
for HER2. Binding leads to blockage, downregulation and internalization of HER2, antigen-
dependent cellular toxicity by the adaptive immune system, induction of apoptosis and 
reduced angiogenesis (201-202). When trastuzumab is administered to patients with HER2 
over expression, relapse rate and overall prognosis improve dramatically (143). If given in 
adjunct to chemotherapy such as a taxane followed by anthracyclines, it reduces the relative 
mortality with as much as 34 % (204-208). Resistance to trastuzumab can appear in both the 
adjuvant and metastatic setting. Early evidence points to an escape-mechanism through 
alterations of the PI3 kinase pathway. Several new drugs have therefore been introduced in 
the last decade, including the tyrosine kinase inhibitor lapatinib that inhibits the ATP-binding 
pocket of HER2 and prevents self-phosphorylation and activation of signal pathways, with 
some effect even in single non-HER2 overexpressing tumors by IHC, and the HER2-HER3 
dimerization antibody pertuzumab (203). In clinical routine, HER2 over expression is 
therefore targeted with a dual blockade, where trastuzumab is combined with pertuzumab. In 
the neoadjuvant and metastatic setting, lapatinib can be added instead, with a slightly 
increased ratio of pathological complete response. Nonetheless, mutations in the intracellular 
kinase domain of HER2, in addition to other escape-mechanisms, can render even the 
intensified HER2-directed therapy ineffective in the long term (139,203). Major side effects 
of anti-HER2 therapy are flu-like symptoms and cardiac dysfunction in as many as 2-7 % of 
patients with trastuzumab (209). The latter is caused by the drug’s downregulation of 
neuregulin-1 (NRG-1), which is essential for survival pathways in cardiomyocytes. 
Therefore, the left ventricle should be examined both before and during treatment (205). 
More than 25 % of patients treated with lapatinib suffer from diarrhea and nausea (130,203). 
Less common side effects of pertuzumab are diarrhea, upper respiratory tract infections, 
rashes, headache, joint pain and fatigue (130,203). 
 The Epidermal growth factor receptor (EGFR) is an alternative pathway to 
target with monoclonal antibody “EGFR inhibitors”. E.g. gefitinib, erlotinib, afatinib, 
brigatinib in lung cancer, and cetuximab in colon cancer. These antibodies block the 
receptors’ extracellular ligand binding domain. Consequently, the receptors cannot longer 
bind the ligand to activate the intracellular tyrosine kinase. Disruption of EGFR can also be 
accomplished by direct action at the tyrosine kinase itself. Compounds such as quinazolines 
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compete with ATP, which is needed for tyrosine kinase activation. Without access to ATP, its 
activity will thereby decrease. Although the EGFR inhibitors are routinely used in other 
cancers, and the quinazolines have been effective and well tolerated in trials, none of them 
have been introduced for the treatment of breast cancer (37,139). 
 
1.5.6 TREATMENT OF HEREDITARY BREAST CANCER 
Most breast cancers are sporadic in the sense that they are caused by de novo genetic events 
during cellular replication, with or without influence of known environmental or lifestyle 
factors. All the same, the hereditary tendency is well documented in breast cancer, either 
through polygenetic alleles with unpredictable levels of risk, or through monogenetic 
syndromes with known major increases in the risk for the disease. Today, 5 to 10 % of all 
breast cancers are caused by known hereditary genetic aberrations (39,210). 
 Genes and loci associated with risk of developing breast cancer can be divided 
into groups with high, intermediate and low penetrance. The distribution of these in the 
population is inverse to their degree of penetrance: High penetrance genes are responsible for 
approximately 25 % of all hereditary breast cancer, while the intermediate and low 
penetrance genes are responsible for the remaining 75 % (210-213). 
 The most well-known high penetrance genes are BRCA1 and BRCA2 (see also 
subsection 1.5.6 on future and experimental treatments). Alone, they cause 5 % of all breast 
cancer cases. BRCA1 and BRCA2 are DNA repair agents that protect the integrity of the 
genome. Having a deactivating germline mutation in either of these genes results in a risk of 
developing breast cancer before the age of 70 of 55 - 65 % for carriers of BRCA1 and 45 % 
for carriers of BRCA2 (39,43,214). Therefore, presymptomatic genetic testing is commonly 
offered to patients in well-known high-risk families, and in the case of a mutation to either 
BRCA1 or BRCA2 prophylactic bilateral mastectomy (215). Other singular genes responsible 
for familiar breast cancer, including PTEN, TP53 and CDH1, are less common in the 
population and have lower penetrance (211). 
 Carriage of mutations in medium penetrance genes, like PALB2, CHEK2, ATM 
or BRIP1 mutants confer moderately increased risk for breast cancer (216-219). These 
mutations are generally not screened for in the clinic, and thereby not treated. This also holds 
true for the vast majority of low penetrance genes. Among the latter, FGFR2 and MAP3K1 
can be mentioned. These encodes for the Fibroblast growth factor receptor 2 - a member of 
the tyrosine kinase receptor family that promotes proliferation, cell motility and angiogenesis 
and the main protein in the mitogenic MAP-kinase signaling pathway. Several thousand more 
remain to be discovered. Most of the hitherto unexplained hereditary risk is thought to be 
caused by these low penetrance variants, together with structural differences, gene-gene 
interactions and gene-environment interactions (216-222). 
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1.5.7 FUTURE AND EXPERIMENTAL TREATMENTS 
Despite being the earliest developed and most frequently used targeted therapy in breast 
cancer, endocrine treatment still has potential for improvement and future use in situations 
beyond the current standard practice. 
Paradoxically, loss of ER expression does not account for most cases of tumor 
recurrence in patients on endocrine treatment. As the vast majority of breast cancers are ER 
positive at diagnosis, the mechanism of this endocrine resistance is currently at the focus of 
intensive preclinical and clinical research including characterization of induced mutations of 
the ER gene through deep genome sequencing. Novel drug candidates target potentially 
upregulated cascades downstream ER, such as the PIK3CA/mTOR and the proliferation-
associated cyclin pathways (70,71,222,223) 
Further, several randomized trials have investigated the role for tamoxifen as a 
preventive agent. Indeed, reduction of relative breast cancer incidence with up to one third 
versus placebo has been shown for up to 10 years after administration of tamoxifen during a 
period of 5 to 8 years. Similarly, AIs such as emestane and anastrozole have reduced the risk 
of invasive breast cancer with up to two thirds. However, many clinicians fruitfully point out 
the low tolerance for potentially grave side effects like thromboembolism, endometrial 
cancer, cataracts and hot flashes in healthy women, and that the absolute risk reduction is 
very limited at 2-3 % (223). In a large cohort of Swedish women (n=70877), Hall and 
colleagues currently seeks to identify a subgroup of women with favorable risk-reward 
profile for preventive tamoxifen treatment. The risk factors studied so far (high 
mammographic density, high mass and microcalcifications) have been identified to increase 
the risk of breast cancer nine fold (224). 
Immune therapy shows great promise in breast cancer, as in other solid tumors. It 
spans a wide range of conceptually distinct approaches, including checkpoint inhibitors, 
antibodies (see also subsection 1.5.5. on anti-HER2 therapy), vaccinations, antibody-drug 
conjugates and targets in the tumor microenvironment. As these treatment modalities evolves 
further and become readily available in the arsenal of oncologists, the demand on the 
diagnostic process and on biomarker analysis to guide patient selection will increase. Immune 
checkpoints refers to inhibitory signals to the T cell receptor. Normally, these exists to 
prevent excessive T cell activation and collateral damage to self tissues when fighting 
pathogens. Tumors can avoid destruction by the immune system by exploitation of 
checkpoints through a plethora of these inhibitory signals. The Cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD1) are two of the 
most frequently studied T cell receptors in this context. Activation of CTLA-4 blocks the 
response of CD8-positive cells, suppresses T helper activation and increases the amount of 
regulatory T-cells, which suppresses immune response. Tumor infiltrating lymphocytes (TIL) 
in breast cancer largely consists of regulatory T-cells, thus potentially aiding the tumor escape 
immune response (225,226). Other studies however, shows a clear survival advantage of 
tumor infiltrating lymphocytes in triple negative breast cancer in terms of reduced risk of 
relapse and death. In HER2 overexpressing tumors, the presence of a lymphocytic infiltration 
in the tumor tissue and stroma has been shown to predict a significantly  treatment response 
with docetaxel added to anthracycline (225). CTLA-4 can be targeted with the monoclonal 
IgG1 antibody ipilimumab and with the IgG2 antibody tremelimumab. The former has been 
FDA-approved for the treatment of skin Melanoma since 2011. The latter is showing 
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promising results in trials with increased immune responses against the tumors, but is not yet 
approved for clinical use. PD1 is constitutively activated in many different tumor types, 
resulting in reduced T cell, B cell and natural killer cell activity. Nivolumab, pembrolizumab 
and atezolizumab are relatively well established antibodies with inhibitory action on PD1. 
Although used in other tumors such as renal cell carcinoma, non-small cell lung cancer and 
melanoma, it is not in current clinical use for breast cancer. Phase 1 trials have shown overall 
response rates in the region of 20 %, with 75 % of the responses in triple negative breast 
cancer, and other trials are ongoing (225). 
Tumor vaccines are aimed at stimulating the adaptive immune system to generate 
memory T cells with potential long-term protection. The biggest obstacle for their use is that 
there are very few antigens that are expressed exclusively in tumor tissue and not at all in 
normal tissue. Further, even in cases where actual tumor specific antigens have been 
identified in individual tumors, they do not seem to be recurring in any larger groups of breast 
cancer patients. Vaccines with HER2-derived peptides have been shown to increase disease-
free survival from 80.2 to 89.7 % at 5 years, at least for patients with low HER2 expression 
(IHC 1 and 2) in a phase I trial. In a phase II trial, a similar vaccine reduced breast cancer 
recurrence in a group of patients with earlier treatment for node-positive or high risk node-
negative disease with more than 50 % (225). 
Antibody-drug conjugates offer an improved way to deliver drugs with high effect but 
low specificity for tumor tissue, such as cytotoxic chemotherapeutic agents. Two complexes 
have made it through at least phase II trials: T-DM1 consists of the HER2-antibody 
trastuzumab coupled with the cytotoxic anti-microtubule agent emtansine. The latter will 
thereby be delivered in increased concentration to tissues with increased HER2 expression, 
i.e. HER2 over expressing breast cancer. So far, the compound has been shown to somewhat 
reduce side effects due to the lower systemic concentration needed and prolong overall 
survival in heavily pre-treated patients as a second-line after treatment with trastuzumab and 
a taxane, compared to lapatinib and capecitabine. Other randomized trials have not been able 
to reproduce this superiority over current standard treatment. MM-302 is another agent, also 
coupled with trastuzumab, in which doxorubicin is delivered in liposomes to HER2 
expressing cells. Early results indicate overall response rates of 12 % and increased 
progression-free survival when compared to cyclophosphamide (225). 
A substantial amount of preclinical and clinical evidence suggests that angiogenesis is 
central to breast cancer growth (as described in subsection 1.2.2), and that increased 
concentrations of the vascular endothelial growth factor (VEGF) is associated with worse 
outcome. Targeting VEGF therefore makes sense. Indeed, in early clinical trials, progression-
free survival doubled when weekly paclitaxel was combined with the anti-VEGF agent 
bevacizumab. However, with longer follow-up, these early trials as well as latter larger well-
powered, placebo-controlled international trials including most subgroups of breast cancer, 
have not been able to reproduce the increased progression-free survival or show increased 
overall survival in patients treated with anti-VEGF including bevacizumab and its later 
followers. Several mechanisms of resistance to anti-VEGF therapy has since been discovered, 
including activation of alternative angiogenic pathways, cell de-differentiation and increased 
aggressiveness from hypoxia and increased numbers of cancer stem cells (208,223,227). 
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Table 4. AJCC prognostic stage groups. T = Primary tumor T category. N = regional lymph 
node category. M = Distant metastasis category (see also Table 3a). HER2 = 
Immunohistochemical, FISH or CISH testing of Human Epidermal growth factor receptor 2 
according to guidelines by the American Society of Clinical Oncology and the College of 
American pathologists. ER, PR = Immunohistochemical testing of Estrogen receptor (ER) 
and Progesterone receptor (PR) according to guidelines by the American Society of Clinical 
Oncology and the College of American pathologists. P = Positive. N = Negative. A = Any. 
*** = Stage group for which the use of grade and prognostic factors changed the group more 
than one stage group from the anatomic stage group (Table 3b). Modified from AJCC Cancer 
staging manual 8th Edition 2017 (104). Reprinted with permission from Springer International 
Publishing. 
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2. AIMS OF THE THESIS 
 
The aim of this thesis is to evaluate immunohistochemical biomarkers currently used in the 
diagnostic process of breast cancer and potential solutions for its improvement. Special 
emphasis is placed on the utility of digital image analysis, Ki67 and other markers for 
proliferative activity. 
 
Aim of paper I: To evaluate the concordance of immunocytochemistry and 
immunohistochemistry in the expression pattern of ERα, PR and Ki67 between fine needle 
aspiration cytology and surgical resections from the same tumors. 
Aim of paper II: To evaluate the concordance of biomarker analyses between currently used 
manual methods and digital image analysis in surgical resections from the same tumors, and 
their correlation to overall survival and gene expression profiles. 
Aim of paper III: To evaluate concordance of immunocytochemistry and 
immunohistochemistry in the expression pattern of ERα, PR, HER2 and Ki67 between fine 
needle aspiration cytology and surgical resections from the same tumors, its impact on 
surrogate subtype classification and correlation to survival. 
Aim of paper IV: To compare the prognostic relevance of proliferational activity as defined 
by the count of mitoses and manually as well as DIA-defined proportions of phosphohistone 
H3- and Ki67-positive cells in different tumor regions.
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3. MATERIALS AND METHODS  
3.1. PATIENT COHORTS  
3.1.1. IMMUNOCHEMISTRY CONCORDANCE COHORT 1 
The first immunochemistry concordance cohort, used in paper I, consists of all patients 
diagnosed with invasive ductal carcinoma NOS or invasive lobular carcinoma of the breast 
during routine work-up of surgical pathology at the Department of Clinical Pathology at the 
Karolinska University Hospital in the year 2011. In total, 454 patients (360 ductal and 94 
lobular carcinomas) were identified. Patients who had received neoadjuvant chemotherapy, 
had not undergone fine needle aspiration cytology (FNAC) or had a delay of longer than 100 
days between FNAC and surgical removal were excluded, resulting in 346 patients. 
Pathological data was then retrospectively extracted from the patient’s digitalized medical 
records. As biomarker assessment was not performed on FNA (immunocytochemistry) in all 
patients, data from 133 patients on ERα status, from 80 patients on PR status and from Ki67 
on 131 patients remained for analysis. 
 
3.1.2. IMMUNOCHEMISTRY CONCORDANCE COHORT 2 
The second immunochemistry concordance cohort, used in paper III, consists of breast cancer 
patients that have performed FNAC at the Department of Clinical Pathology at the 
Karolinska University Hospital during 2005 and 2006. In total, 1671 patients were identified. 
After exclusion of benign lesions, relapses and cases without Ki67 assessment, 517 patients 
remained. The consecutive surgical resections including Ki67 assessment were analyzed at 
the Department of Clinical Pathology, Karolinska University Hospital or at the Department of 
Clinical Pathology, Capio S:t Göran Hospital. Of 392 cases with both Ki67 evaluations by 
ICC from aspiration cytology and by IHC from resection specimen, 301 were included for 
Ki67 assessment. Reasons for exclusion were: Neoadjuvant treatment (n=43), no numeric 
Ki67-value (n=39), previous breast cancer diagnosis within 5 years (n=9), patients with stage 
IV disease (n=0). In total, 299 patients remained with 301 invasive tumors of the breast (256 
invasive carcinoma of no special type/ductal carcinoma, 22 invasive lobular carcinoma, 23 
other or missing data). Further data on adjuvant treatment, relapse or distant metastasis and 
survival for the included patients was obtained from the digitalized patient medical record 
system. All events of breast cancer recurrence, loco regional- and distant metastasis as well as 
date and cause of death were gathered from detailed clinical follow-up history and the cause 
of death certificate, when available. Overall survival was defined as time from date of 
diagnosis to death or end of follow-up and breast cancer specific survival was defined as 
patients who had not died from breast cancer disease by end of follow-up. 
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3.1.3. UPPSALA COHORT 
The Uppsala breast cancer cohort, used in paper II and previous publications (83,228-230), 
consists of altogether 315 patients diagnosed with invasive breast cancer in Uppsala County, 
Sweden, between the years 1987 and 1989. This represents 65 % of all patients diagnosed 
with breast cancer in Uppsala during the period. The clinical data and pathological 
characteristics of the tumors were collected from the patients’ medical records. Using 
registries, follow up has been updated several times by examining the survival status of the 
patients together with the cause of death. Global gene expression analysis was performed 
using Affymetrix microarray chips on 260 of the patients within the cohort. The analysis was 
performed on all the patients which had sufficient and high enough quality mRNA. The 
tumors were then classified into the intrinsic subtypes Luminal A, Luminal B, Basal-like and 
HER2-enriched. Due to the construction of TMAs from the original formalin fixed paraffin 
embedded (FFPE) tumor tissues, the cohort can still today be used to examine the expression 
levels of potential novel cancer biomarkers using immunohistochemistry (IHC) techniques.  
 
3.1.4. STOCKHOLM COHORT 
The Stockholm breast cancer cohort, used in studies II and IV and previous publications 
(83,231), consists of patients from Stockholm and Gotland counties, Sweden, with invasive 
breast cancer that was surgically removed between January 1st 1994 to December 31st 1996. 
280 of these had available FFPE tumor tissue. Clinical and pathological data for tumor size, 
lymph node status, hormone receptor status, treatment, date and site of relapse and cause of 
death, were collected from the Stockholm-Gotland breast cancer registry. The histological 
grade was re-examined by an experienced pathologist. 159 remaining tumors were examined 
using global gene expression microarray chips from Affymetrix. Reasons for exclusion from 
the gene expression analysis were lack of available frozen tumor tissue, emigration abroad or 
refusal to participate, low quality or low amounts of extracted RNA, or that the patient had 
received neoadjuvant therapy. The patients excluded because of lack of frozen tissue had on 
average smaller tumor size, fewer affected lymph nodes and less recurrences. However, the 
patients excluded due to other reasons did not differ from the patients included in on the 
microarray analysis. 
 
3.1.5. CLINSEQ COHORT 
The Clinseq (“Clinical sequencing of cancer in Sweden”) breast cancer cohort was used in 
paper II, III and IV. It consists of both fresh frozen and paraffin-embedded breast cancer 
tissue from patients who underwent surgery at the Karolinska University Hospital from 
November 1st 2002 to December 31st 2010. The patients were identified in the Stockholm–
Gotland breast cancer registry and digitalized patients’ medical records, along with clinical 
data and results from manual immunohistochemical evaluations as well as HER2 FISH. 
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Haematoxylin and eosin-stained slides were used for selection of invasive tumor areas 
without carcinoma in situ, intense inflammation, fibrosis, necrosis, or poor fixation. 4–8 
tissue cores (Ø 0.8 mm) per patient were then mounted into a tissue microarray using a semi-
automated instrument (Minicore 3, Tissue Arrayer, Alphelys, France). These tissue 
microarrays were stained with ER, PR, and HER2. In contrast, full sections were used for the 
staining of Ki67, considering the heterogeneous distribution of this marker. A total of 195 
patients remained for analysis after exclusions of patients with incomplete PAM50 gene 
assay data and/or clinical immunohistochemical data, tissue microarray cores with <100 
tumor cells, failed digital scanning, and errors in software operation. For paper IV, survival 
data of up to 14 years was added to the cohort. 
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3.2. TISSUE SAMPLES AND LABORATORY METHODS 
3.2.1. FORMALIN FIXED PARAFFIN EMBEDDED TUMOR TISSUE 
Archives of formalin fixed paraffin embedded (FFPE) tissue blocks are very important 
sources of material and data in the fields of oncology and pathology. After surgical removal 
of a tumor, the tissue is placed in 4 % formaldehyde for fixation. It is then cut into smaller 
pieces that can be embedded in paraffin blocks. In many cases, this step is performed by 
pathologists for selection of preferred and representative regions of the tissue. The paraffin 
embedded tissue blocks are cut into sections of 3-4 µm and mounted on a glass slide. These 
thin sections are then finally stained for pathological evaluation and diagnosis under the 
microscope. Hundreds of different stains are currently in clinical use. By routine, most 
specimens are stained with Haematoxylin and eosin. In breast cancer, immunohistochemical 
stains of ER, PR, HER2 and Ki67 are commonly added (76,98). 
 After diagnosis, most clinical pathology units archive the remaining FFPE to 
enable further tests and future re-analysis. With approval from an ethical review board, these 
can also be used for research purposes. Commonly, they are used to examine the tumors’ 
expression of selected proteins using methods such as immunohistochemistry (IHC) or 
immunofluorescence (IF). The advent of next generation sequencing (NGS) techniques and 
the refinement of gene expression arrays have made it possible to use FFPE for examinations 
of its genetic profile on a DNA and RNA level (81,84). The benefits using these FFPE 
collections instead of fresh material is that it allows for long follow-up times and large 
numbers of available tumors. To some degree, the quality of the RNA and DNA that can be 
extracted from the FFPE is however still inferior to the quality that can be achieved with the 
gold standard fresh frozen tissue. 
 
3.2.2. IMMUNOHISTOCHEMISTRY AND IMMUNOCYTOCHEMISTRY  
In simple terms, DNA is the recipe for proteins. What specific proteins a cell produce, 
thereby defining the nature and functions of that cell, is determined by what mRNA is 
translated. In other words, far from all genes is actively expressed in all cells. 
 In cancer, the expression of proteins is often dysregulated. Both abundance and 
lack of certain proteins is a common feature. This can be used in both the clinical and 
research setting, as the abnormal presence of a protein can signal the presence of cancer and 
the biological characteristic of that cancer. In a way, dysregulated protein expression is also a 
signal to the immune system, in many cases triggering an eradicating response (36). Protein 
expression can be directly illustrated through the similar techniques of immunohistochemistry 
(IHC) and immunocytochemistry (ICC) (94,232,233). IHC is performed on histological tissue 
sections whereas ICC is performed on aspirated cytological material without intact 
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anatomical tissue structure. When the latter is performed as a direct smear, the evaluation of 
cells and protein expression can be completed within minutes from aspiration from the 
patient, whereas IHC typically requires a couple of days for fixation, paraffin embedment, 
cutting and staining. An advantage of IHC is the spatial information on where within a tumor 
or other tissue a protein is expressed. This allows for visual assessment of the site of 
expression, in contrast to other methods such as ICC, flow cytometry or Western blotting. 
Both IHC and ICC are based on the ability of the adaptive immune system to produce 
antibodies with specific affinities to different proteins. These antibodies are produced in two 
principally different ways: 
 Many clones used in clinical routine have been formed in animal hosts, like 
rabbits or mice that have been inoculated with a target protein such as the human estrogen 
receptor. The ER protein is identified as foreign, which triggers immune responses and 
intense secretion of antibodies that can be harvested for use on human tissues. In the case of 
monoclonal antibodies, a specific sample of immune tissue is isolated and used for creating 
immortalized cell lines that keep producing antibodies with high specificity for a single 
antigen. Polyclonal antibodies are sampled from the whole serum of the inoculated animal. 
Thereby, higher sensitivity but less specificity is achieved. Once the antibodies are isolated, 
they are usually conjugated to an enzyme that can catalyze a color-producing reaction that is 
visually detectable in the light microscope. In this example, cells expressing ER are easily 
detected by a brown color, contrasting to the usually light bluish haematoxylin counterstain. 
Note that this method of producing diagnostic antibodies is not far from the method used for 
creating monoclonal therapeutic antibodies like trastuzumab. In order not to trigger an 
immune response against the mouse antibody protein in the patient, trastuzumab is 
humanized. This is a process in which proteins are modified to increase their similarity to 
antibody variants produced naturally in humans. Usually, this is done by using recombinant 
DNA injected in immortalized cells grown in a bioreactor, only using mouse DNA for the 
complementarity determining region segments responsible for the ability of the antibody to 
bind to its target antigen (232,233). 
 The alternative method for IHC/ICC antibody production uses such 
immortalized bioreactor cells that have been injected with gene fragments corresponding to a 
specific epitope. This allows for production of monoclonal antibodies that ideally target only 
one specific region of the protein of interest. There is however always some degree of cross 
reactivity, resulting in false positive results (232,233). 
 Several procedures can be performed to assure oneself of the specificity of the 
antibodies. Before using antibodies to detect proteins by IHC or ICC, all nonspecific epitopes 
on the tissue sample should be blocked in a blocking buffer to prevent nonspecific binding of 
the antibodies. Otherwise, the antibodies or other detection reagents may bind to any epitopes 
on the sample, independent of specificity. One should also expect diminished staining of the 
antibody in a culture or tissue where the protein has been knocked out. Other biochemical 
methods, such as Western blotting, are commonly used for validation. 
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 One of the main challenges of IHC and ICC is to turn the vast and complex 
visual information on protein expression in a tissue section into standardized, quantified and 
reproducible data. Evaluation of IHC and ICC is by routine a manual task, requiring 
meticulous adherence to protocols. For evaluation of Ki67 expression in breast cancer, ≥ 
1000 cells should be counted, and what region to score depends on the distribution of 
positively stained cells. Even if two pathologists would agree on an exact proportion of Ki67-
positive to total tumor cells, e.g. 17 %, no undisputable consensus exists to help determine if 
this constitutes a “high” or “low” proliferational rate (76, 94-97). As mentioned previously, 
digital image analysis has been suggested as a way to improve the evaluation of IHC, and to a 
lesser extent ICC (76). 
 
3.2.3. VISIOPHARM INTEGRATOR SYSTEM 
The DIA software used in papers II and IV is the Visiopharm Integrator System (VIS), 
supplied under the non commercial terms of a collaboration with Visiopharm A/S, 
Hoersholm, Denmark. This software can be made into an illustrating example of the current 
state of the field: VIS utilizes a method for tissue classification based on virtual double 
staining, which automatically distinguish epithelial- from stromal tissue. In short, after being 
digitally scanned at x20, each biomarker slide is aligned with an adjacent 3 µm slide stained 
immunohistochemically for a pancytokeratin marker such as CkMNF 116. This enables 
automatic exclusion of non-epithelial cells that potentially express the biomarker in question, 
i.e. proliferating Ki67-positive lymphocytes. Thus, only cells that express cytokeratin are 
eligible for detection of positivity or negativity for a second immunohistochemical stain, like 
ER, PR, KI67, HER2 or PHH3. Individual applications (Apps) for each of these then run the 
scoring of positive and negative cells itself, with sub-cellular resolution (234). Growing 
evidence points to the advantages in congruence to gene expression assays, sensitivity and 
specificity for the Luminal B subtype and prognostic power of DIA compared to current 
manual methods of biomarker assessments (159-162, see also section 1.4). 
 
3.2.4. PAM50 GENE EXPRESSION ASSAY 
Tissue from the tumors in paper II and IV were snap frozen after surgical resection. These 
tissues were then used for extraction of RNA (DNA/RNA/protein mini kit, Qiagen, Hilden, 
Germany). The obtained RNA was then assessed to ensure sufficient quality by a 
standardized protocol (RNA integrity number). 1 µg of RNA was used for rRNA depletion 
using a removal method (Ribo-Zero removal kit, Illumina, San Diego, CA, USA). Libraries 
of stranded RNA sequences were then constructed (TruSeq Stranded Total RNA Library Prep 
Kit, Illumina). Gene-level expression estimates were calculated and normalized using HTSeq 
count version 0.6.1 and edgeR, which are packages for the Python and R programming 
languages that provides infrastructure to process data from high-throughput sequencing 
assays (235,236). A data library from the “Cancer Genome Atlas” by the National Cancer 
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Institute and National Human Genome Research Institute (n = 1073) were run in parallel for 
reference (234). Further, the reference data was used to train a nearest shrunken centroid 
classifier for each gene in the PAM50 gene set (78). Variances between our material and the 
data from the “Cancer Genome Atlas” were then mean-centered and scaled to unit variance. 
Last, each tumor in our material was classified into one of the intrinsic subtypes Luminal A, 
Luminal B, HER2-enriched or basal-like. 
 This procedure is in accordance with the method of assigning intrinsic subtype 
based on the PAM50 gene set used elsewhere (77,78,80-88,237,238) (see also subsection 
1.3.4). 
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3.3. STATISTICS 
Several statistical methods and tests have been performed during the work with the different 
papers in this thesis. 
 Repeatedly, Student’s T-tests have been performed to determine whether two 
sets of normal distributed data differ significantly from each other. Where the data has not 
followed a normal distribution, the similar Mann-Whitney U test has been performed. 
For a determination of suitable threshold for a continuous variable in relation to 
a binary classifier system, e.g. what percentage of Ki67 or PHH3-stained cells that has the 
best specificity and sensitivity for PAM50 Luminal B versus PAM50 Luminal A status, the 
points on receiver operating characteristics curves method has been used. In all papers, equal 
emphasis were put on achieving best possible sensitivity and specificity without one taking 
precedence over the other. 
 For comparisons of classification concordance between two different methods, 
such as manual and DIA surrogate subclassification to PAM50 gene expression assays, 
Cohen’s kappa statistics and percentages of concordant cases were computed. 
 Medical research in Sweden is facilitated to a large extent by the existence of 
personal identification numbers. These are attached to each individual and will not vary in 
relation to insurance companies, health care providers, banks or other authorities. Thereby, 
registers are usually easily cross-referenced once a researcher obtains access to them (with 
approval from an ethical review board). Consequently, data on diagnosis, treatment and 
survival is usually of excellent quality. In this context, the data can be used to examine 
prognostic values of novel biomarkers, or of older biomarkers tested with novel techniques. 
 The Kaplan-Meier method has been repeatedly used to estimate and visualize 
survival across different subgroups of our breast cancer patients. The Cox proportional hazard 
model has been used to test survival differences between different groups and calculate 
hazard ratios. 
 To compare individual methods ability to discriminate between different 
prognostic groups, the likelihood ratio test (LR χ2) was performed. In short, this is a test of 
the sufficiency of a smaller model versus a more complex model. The higher the χ2 statistic, 
the higher the prognostic information contained in the model. The null hypothesis of the test 
states that the smaller model provides as good a fit for the data as the larger model. If the null 
hypothesis is rejected, then the alternative, larger model provides a significant improvement 
over the smaller model. Likelihood ratio chi-square changes (LR -Δχ2) were computed for a 
test of the relative amount of prognostic information in the different methods in an attempt to 
answer questions like: Will significantly more prognostic information be obtained if a new 
method is added to an old? 
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 Where survival data wasn’t available, Spearman's rank-order correlations were 
run to determine the relationship between biomarkers and other characteristics that are known 
to correlate with survival, i.e. the Nottingham combined histologic grade, primary tumor 
diameter and axillary lymph node status. Throughout all papers, differences with a p < 0.05 
were considered significant, and all p were two-sided. 
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4. RESULTS AND DISCUSSION 
4.1. PAPER I  
“Low concordance of biomarkers in histopathological and cytological material from breast 
cancer”  
 
Stringent evaluation of biomarkers such as ER, PR and Ki67 is essential for the correct 
treatment of breast cancer patients. In this study, we collected retrospective data from paired 
ICC and IHC evaluations of 346 tumors (Immunochemistry concordance cohort 1, as 
described in subsection 3.1.1). As an early step in the diagnosis of a breast lump, detected by 
palpation or mammography, fine needle aspiration cytology is commonly performed. This 
material is then sometimes stained using ICC of selected biomarkers. Perhaps only intended 
to aid the cytologist’s decision on whether the lump is a breast cancer or not, the results of the 
ICC also has some degree of influence on decisions of treatment. This is especially manifest 
in the metastatic setting, where fine needle aspiration cytology is often the only available 
source of material. IHC is still considered the gold standard when defining surrogate 
subtypes, and also the material used in the vast majority of the literature on evaluation of 
immunochemical markers in breast cancer. Consequently, it is very important that there is a 
high correlation between ICC and IHC.  
 Therefore, we compared the concordance of ICC and IHC regarding the results 
of ER, PR and Ki67 evaluations. In total, we had access to data from both IHC and ICC on 
133 patients for ER, 80 patients for PR and 131 patients for Ki67. We found that in average, 
the proportion of ER-positive cells using ICC was 10.6 percentage points lower than when 
the same tumor was evaluated using IHC. When comparing tumor status as either “ER 
positive” or “ER negative”, a major predictive and prognostic difference as it distinguish 
luminal tumors with expected response to endocrine treatment from non-luminal tumors (see 
also subsection 1.5.3 on endocrine treatment), using first 1 % and the 10 % positive cells as a 
threshold, 9.0 % and 10.5 % of the tumors, respectively, switched status from ICC to IHC. 
Similarly when evaluating PR, the expression was in average 13.6 percentage points lower 
using ICC than IHC. Using a 1 % or 10 % threshold to discriminate “PR positive” from “PR 
negative”, 7.5 % and 11.3 % of the tumors switched status from ICC to IHC, respectively. 
 When comparing the scoring of Ki67 expression, the expression was in average 
7.9 percentage points lower by ICC than by IHC. Because there is no consensus threshold for 
labeling a tumor’s Ki67 positivity or proliferational rate as either “high” or “low”, we used 
the two different thresholds of 14 and 20 %, that also have been used by previous authors 
(74-76). When using the 14 % cutoff, 32.8 % of the tumors changed proliferation 
classification from “low” to “high” or vice versa from ICC to IHC. With a threshold of 20 %, 
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29.8 % of the tumors were reclassified. We also showed that by adjusting the cutoffs used for 
ICC classification of Ki67 from 14 % to 10 %, the number of patients that were reclassified 
was slightly decreased. 
 We observed both over- and underestimation of ER, PR and Ki67 when 
comparing ICC to IHC on individual cases. On average although, ICC systemically under-
classified all three biomarkers. There could be several reasons for this, where one is the 
difference in the time point from when the samples were collected as FNAC can precede the 
surgery by months. Another reason is that sampling using FNAC represents a random small 
area of the tumor compared to the complete tumor evaluation by IHC. This is especially 
apparent for Ki67, since the recommendation is to evaluate the expression in different areas 
based on the pattern of expression across the tumor section. Using ICC it is impossible to 
know if the sample has been extracted from an area of relatively high or relatively low 
expression within the tumor. In addition differences in fixation and preparation process are 
common between ICC and IHC and have been shown to cause variances in the intensity of 
staining. This is mainly believed to happen through differences in the deterioration rate of the 
biomarker. 
 When evaluating the data, we observed that a disproportional high number of 
the ER and PR evaluations were concentrated in the vicinity of 10 % positive cells. This was 
seen in both ICC and IHC evaluations, but was more common for ICC. The reason for this 
may perhaps be explained by a will of the cytologist and pathologist to not under-diagnose 
patients. This bias could be introduced unconsciously, to not withhold patients from 
endocrine treatment that is considered both efficient and safe. Additionally, it cannot be 
excluded that since the ICC evaluation is usually followed by an IHC evaluation, which the 
treatment should be based upon, the perceived need for precision of ICC evaluation 
decreases. 
 Novel techniques of liquid and paraffin based ICC has been shown to improve 
concordance with IHC evaluations. It is therefore important that pathological and cytological 
labs consider implementing these techniques. Evaluation of the correlation between ICC and 
IHC is important to decrease the variability of biomarker assessment, especially considering 
the limited alternatives in the metastatic setting.
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4.2. PAPER II 
“Digital image analysis outperforms manual biomarker assessment in breast cancer” 
 
In order to suggest concrete methods of improving surrogate IHC-based concordance to gene 
expression tests, we evaluated DIA as an alternative to the currently used manual methods of 
biomarker scoring. In this study, we used the Stockholm and Clinseq cohorts (as described in 
subsections 3.1.4. and 3.1.5, respectively) and the TMA-based Uppsala cohort (subsection 
3.1.3.) for a total n = 436. For these patients, we had access to up to 28 years of survival data. 
The tumors were scored for Ki67, ER, PR, and HER2 status manually and by DIA. The 
results were then compared for their concordance to PAM50 assays in subtype classification 
and prognostic power in terms of Cox regression likelihood ratios (LR χ2) as well as 
sensitivity and specificity for the Luminal B subtype. The DIA system used was the 
Visiopharm Integrator System (subsection 3.2.3). 
 All tested DIA methods of scoring Ki67 outperformed even our most accurate 
pathologist’s manual scores in terms of sensitivity (Sn) and specificity (Sp) for the Luminal B 
subtype (DIA Ki67 hot spot Sn 86 % Sp 77 % vs. manual Ki67 Sn 74 % Sp 75 %). When 
comparing DIA versus manual immunohistochemical surrogate concordance with PAM50 
gene expression assays, all tested DIA methods were superior to the manual method. The 
hazard ratios for all-cause mortality in tumors with a ‘high’ vs ‘low’ Ki67 index as defined by 
manual methods and DIA were equivalent. With regard to tumor region, Spearman’s rank-
order correlations showed a positive and significant correlation with histological grade for 
both manual and DIA methods, with the strongest correlation for the DIA method giving an 
automatic representation of the average Ki67 positivity across the full tumor cross-section (rs 
= 0.575, p < 0.001) and the weakest for the manual scores (rs=0.459, p < 0.001). When the 
prognostic value of a Ki67 index determined by each of the manual and DIA scoring methods 
was tested, all contributed with significant information on overall survival in the PAM50 
Luminal A and B subtype tumors, with the highest LR χ2 for DIA of Ki67 in hot spots (LR 
χ2 = 7.22, p = 0.007). Furthermore, DIA of Ki67 in hot spots added significantly more 
prognostic information than the manual scoring method in the same subgroup. This was 
however not the case when we included all PAM50 subtypes, confirming that the prognostic 
role for Ki67 is mainly related to the Luminal A and B subtypes. The expression of Ki67 was 
indeed different in different tumor regions. This did not induce any major differences in 
performance of subclassification or prognostication as long as the thresholds for “high” vs. 
“low” proliferation was adjusted accordingly, except for DIA of Ki67 in ‘hot spots’ that had a 
slightly better prognostic value. 
 In summary of this study, manual assessments of the biomarkers HER2, ER, 
PR and Ki67 with an emphasis on the latter, was in most aspects an inferior alternative to 
digital image analysis. This implicates that in current clinical routine, an avoidable high 
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proportion of patients risks being treated with potentially harmful agents such as cytotoxic 
chemotherapy without benefit, or being excluded from the beneficial treatments the DIA 
method would indicate.  
 Accordingly, we concluded that DIA is a viable and competitive alternative for 
biomarker testing in breast cancer. We strongly encourage further studies to confirm the 
results found here in larger populations, to provide data on cost-benefit ratios, to facilitate 
implementation and to evaluate the performance of digital image analysis in prospective 
clinical use.
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4.3. PAPER III 
“Biomarker assessment in cytology and corresponding resected breast 
tumors—correlation to molecular subtypes and outcome in primary 
breast cancer” 
 
In this study, we evolved the concept of study I with an evaluation of the concordance of 
consecutive ICC and IHC assessments performed on paired fine needle aspirations and 
resected tumor specimens, respectively. Furthermore, we investigated how a status of Ki67 
“low” and “high” with ICC and IHC corresponded to overall survival. The immunochemistry 
concordance cohort 2 and Clinseq cohorts were used (see subsections 3.1.2. and 3.1.5) for a 
total n = 495. Ki67 assessments, as well as ER, PR and HER2 when available, were analyzed. 
Clinicopathological data, including up to 10-year overall survival, was retrospectively 
gathered from patient medical record systems. PAM50 subtype data was used to correlate 
surrogate subtypes to gene expression subtypes. 
Ki67-indices varied between ICC and IHC, and were prone to switch between low- 
and high proliferation within the same tumor. ER evaluations were discordant in 5.3 % of the 
tumors, which in the clinical setting would mean that 1/20 patients would risk being left out 
of beneficial endocrine treatment or being given it without benefit. Discordance with PAM50 
subtypes was seen in 40 % of the cases with ICC, and in 36 % with IHC. Patients with IHC 
Ki67 “high”, in this study defined as a proportion of Ki67-positive cell above the 67th 
percentile of the material, had significantly worse survival than patients with IHC Ki67 below 
this threshold, and a significantly higher hazard for all-cause mortality at 10 years (HR 1.75, 
95% CI 1.01-2.80, p = 0.02). Additionally, these patients had a significantly higher 
probability for axillary lymph node metastasis. No significant differences in survival or risk 
for axillary lymph node metastasis could be shown between ICC Ki67 “high” and “low”. 
In summary, this study adds to the results of paper I, in which we showed a 
discordance of ICC and IHC. By including survival data, we now conclude that not merely 
are the methods discordant, but ICC fails to provide prognostic information. Consequently, 
IHC is the superior method of Ki67 assessment. Although FNAC can still have an important 
role in distinguishing malignant from benign epithelium, these findings consequently do not 
support the use of direct smear ICC Ki67 to draw other conclusions than diagnosis when IHC 
is available in the clinical setting.
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4.4. PAPER IV 
“Digital image analysis of Ki67 in hot spots is superior to manual Ki67, phosphohistone H3 
and mitotic counts in breast cancer” 
 
In this paper, we compared the prognostic value of mitoses, Ki67 and the more recently 
described Phosphohistone H3, when evaluated by manual methods and DIA in two cohorts of 
primary breast cancer specimens (total n=294). 
 Proliferative activity is one of the most important prognostic parameters in 
cancer. By international standards, it is routinely evaluated by a count of mitoses during the 
pathological examination of breast tumors. Adding immunohistochemical stains of the 
nuclear protein Ki67 provides extra prognostic and predictive information. However, the 
currently used methods for both of these evaluations have some substantial limitations, 
primarily in terms of reproducibility. Importantly, it is still unclear whether analysis of Ki67 
should be performed in the tumors’ hot spot – i.e. the area where the biomarker is expressed 
in the relatively highest proportion of tumor cells, in the tumor periphery – i.e. the border 
region formed by the invasive tumor cells and the surrounding stroma, or as the average 
proportion of Ki67-positive cells across the whole tumor section. 
 In this paper, both manual and DIA scores of Ki67 and PHH3 were evaluated 
along with mitotic counts for their sensitivity and specificity for the gene expression based 
Luminal B versus A breast cancer subtypes, for the high versus low transcriptomic grade 
based on gene- and isoform-level expression data from RNA-sequencing (121), for axillary 
lymph node status as well as for their prognostic value in terms of Cox regression hazard 
ratios (HR) and prediction of breast cancer specific and overall survival. 
Especially evident in the tumors’ hot spots, digital image analysis of Ki67 
outperformed the other markers in sensitivity and specificity for gene expression Luminal A 
and B subtypes (DIA Ki67 hot spot Sn 81.5 % Sp 65.6 %. PHH3 Sn 68.5 % Sp 71.2 %. 
Mitotic counts Sn 77.8 % Sp 45.2 %) as well as in sensitivity and specificity for the 
transcriptomic grades. In contrast to mitotic counts, tumors with high expression of Ki67 as 
defined by digital image analysis, and high numbers of Phosphohistone H3-positive cells, had 
significantly increased HR for all-cause mortality within 10 years from diagnosis (HR 2.93, 
95 % CI 1.61–5.31 for DIA of Ki67 in hot spots vs. HR 1.89, 95 % CI 0.66–5.46 for manual 
assessment of the number of mitoses in 10 high power microscopic fields). Further, DIA of 
Ki67 was superior to manual Ki67 and PHH3 evaluations as well as to mitotic counts in 
terms of separation of patients with poor versus relatively good overall survival. 
Finally, we replaced the manual mitotic counts with digital image analysis of Ki67 in 
hot spots as the marker for proliferation when determining histological grade. This increased 
differences in estimated mean overall survival between the highest and lowest grades (3.4 
years vs. 2.1 years between the classic Nottingham combined histological grades 1 and 3) and 
added significantly more prognostic information. We conclude that digital image analysis of 
Ki67 in hot spots might be suggested as the marker of choice for proliferative activity in 
breast cancer.
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4.5. GENERAL DISCUSSION AND FUTURE PERSPECTIVES  
 
The diagnostics and treatment of breast cancer has improved drastically in the last several 
decades or even the last century. This is especially evident for early breast cancer given 
neoadjuvant or adjuvant treatment, where targeted therapies like trastuzumab have led to a 
dramatic reduction of recurrences. Most, but not all, patients now have a good prognosis. 
Accurate and reliable identification of the different subtypes of the disease, including the 
most aggressive ones, is therefore key in further advancing the field. 
 Improved evaluations of markers for these different subtypes and predicted 
therapy responses holds promise in serving this end, regardless if these markers are based on 
gene expression profiles, immunohistochemistry or other techniques. Fine needle aspirations 
are safe, reliable and cost efficient in identifying malignant cells. In certain situations they are 
also the only practical way of obtaining material for analysis: As it has been shown that 
tumor characteristics transform during disease progression and that biomarker profiles 
frequently change from primary tumor to metastasis, one cannot rely on findings from 
immunohistochemistry of the primary tumor to draw conclusion on the metastasis (239). 
Therefore, the metastasis will have to be sampled separately and the biomarkers reassessed, 
ideally with immunohistochemistry (240). But due to anatomic location, size and 
accessibility of the metastatis, fine needle aspirations are sometimes the only available option. 
Consequently, it is crucial that the results of immunocytochemistry and 
immunohistochemistry are concordant. In this context, it is important to highlight that the 
findings of two of the papers presented in this thesis suggest that outcomes of the two 
methods actually do differ. Tumors classified as negative for the Estrogen receptor with one 
method might be classified as positive with the other, resulting in an altogether different 
treatment strategy. When it is possible to choose between fine needle aspirations and 
obtaining material for immunohistochemistry through a core needle or incisional biopsy, our 
results indicate that one should choose the latter. This is not indicating an opinion on our 
behalf that fine needle aspirations are obsolete per se. In the event future developments allow 
for sequencing of all tumors on the RNA or DNA level to fine tune treatment (“precision 
medicine”), the fine needle might prove to be a reliable source of material provided enough 
can be aspirated. 
 Regarding digital image analysis, one might argue that it is only complicating a 
fairly straightforward task of counting stained and unstained cells, and that it is not user 
friendly enough in comparison with eyeballing a glass slide under the light microscope. Its 
potential is indeed fairly limited, as even a perfect immunohistochemical test still would be 
nothing but a surrogate for the gene expression assays in many clinical applications. Simply 
put: You can never obtain perfect understanding of something by measuring something else. 
Substantial investments in digital scanning capacity, data storage, software, and training are 
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required at each institution before effective use of the technology can be expected. And with 
an excessive automation, DIA could withdraw some degree of control over the biomarker 
assessments, potentially leading to dire consequences to patients. Furthermore, DIA may in 
itself be a source of variance. Different DIA approaches will inherently classify tumor, nuclei, 
and membranes differently, and poor performance of the algorithm’s identification of tumor 
versus non-tumor tissue as well as cellular components would be a significant source of error.  
 To minimize the variance contributed by the digital image analysis software, 
and to reassure the medical field of the validity of its results, the industry must make sure 
they do not deliver “black boxes” to the clinical end users. Strict industry standards, perhaps a 
comprehensible and easily verifiable version of the rules governing medicinal products in the 
European Union (EUDRALEX) should be agreed upon (241). Further, each manufacturer 
should strive for the maximum possible degree of transparency in how their product handle 
and analyze the tissues, and towards producing interoperable hard- and software and 
standardized file formats, such as the DICOM standard for medical imaging (242). 
 When interpreting the results of any method’s concordance to gene expression 
assays, one should also note that any tumor’s subtype is based on the average gene expression 
profile in the very piece of tumor tissue from which RNA was extracted. Thus, presence of 
substantial intratumor heterogeneity could potentially lead to uncertainty in subtype 
assignment and consequentially impact the immunohistochemical versus PAM50 subtype 
concordance. In an ongoing study we seek to shed clarity to this subject (unpublished). So 
far, our preliminary data indicates that intratumor heterogeneity in terms of PAM50 subtype 
is quite limited and not a common occurrence. Simultaneously, one should keep in mind that 
the gene expression panels frequently mentioned here should not be viewed as the final truth 
on breast cancer subclasses. In the near future, whole exome or even whole genome 
sequencing might be standard practice in clinical breast cancer diagnostics (243,244). 
Moreover, manual versus digital image analysis immunohistochemical subtype concordance 
to PAM50 assays would be influenced to a similar degree by a presence of intratumor 
heterogeneity, why we believe that it is not likely to affect the results and conclusions of this 
study in any major way. 
 And after all, digital image analysis is in many ways already an accessible, 
reliable and simple option with superior reproducibility (160-163). The industry has left the 
early, experimental days behind and can now offer several mature systems for immediate 
introduction in clinical routine. A growing number of applications are offered on the market, 
including the one tested in two of the papers presented this thesis. Combined with 
increasingly efficient and affordable digital glass slide scanners, digital pathology is now 
challenging manual biomarker scoring for the method of choice. In addition to its  
competitive performance, digital image analysis provides an opportunity for strained 
healthcare institutions to reduce time consumption for pathologists and to allocate precious 
resources to more qualified tasks. When digital image analysis operations are fully 
automatized, manual input and thereby the sampling bias can be reduced to a minimum. This 
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could potentially allow for biomedical scientists or other laboratory personnel with only a 
basic understanding of histopathology and immunohistochemistry to manage biomarker 
testing, including surrogate immunohistochemical subclassification in breast cancer. 
 Although unexplored, a near future development to be expected is the 
introduction of artificial intelligence (AI) and deep learning algorithms for the interpretation 
of digitalized tissue and tumor images. In contrast to the software tested in this thesis that 
does no more or no less than what it’s originally told, AI relies on computational methods 
that allows for a degree of self-programming by learning from an initial set of examples that 
demonstrates the desired behavior. Recently, Webster and colleagues, sponsored by Google 
Inc., trained such an algorithm to identify diabetic retinopathy on a retrospective set of more 
than 100 000 retinal images. When this algorithm was applied on 2 separate cohorts, it 
operated with a sensitivity and specificity well over 90 %, and an area under the receiver 
operating curve of 0.991 (245). 
 Finally, it should be noted that the results of AI-based image interpretation, 
DIA and any other visual method might be viewed as more than mere surrogates for other 
more sophisticated tests, such as gene expression assays. It is not a law of nature that 
subclassification, prognostication and therapy selection must be based on RNA or DNA 
profiles. Depending on future developments of this field, any of a large number of methods 
might see a share of diagnostic use, and immunohistochemistry is set to retain a place when 
assessing protein expression. 
 In conclusion, we acknowledge the objections that might be raised against 
digital image analysis and recommend pathologists and laboratories to proceed with 
reasonable deliberation when acquiring equipment and selecting software. In this sense, the 
introduction of digital image analysis should not differ from the general level of precaution 
used when introducing any novel technique. If anything, the results of the papers presented in 
this thesis gives us confidence to recommend an automated analysis as a solution to some of 
the long standing problems of tumor classification based on immunohistochemical stains. 
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